U.S. patent application number 12/791517 was filed with the patent office on 2011-04-07 for peptidomimetic inhibitors of post-proline cleaving enzymes.
This patent application is currently assigned to Trustees of Tufts College. Invention is credited to William W. Bachovchin.
Application Number | 20110082108 12/791517 |
Document ID | / |
Family ID | 26988769 |
Filed Date | 2011-04-07 |
United States Patent
Application |
20110082108 |
Kind Code |
A1 |
Bachovchin; William W. |
April 7, 2011 |
Peptidomimetic Inhibitors of Post-Proline Cleaving Enzymes
Abstract
The present invention relates to inhibitors of post-proline
cleavage enzymes, such as inhibitors of dipeptidyl peptidase IV, as
well as pharmaceutical compositions thereof, and methods for using
such inhibitors. In particular, the inhibitors of the present
invention are improved over those in the prior art by selection of
particular classes of side chains in the P1 and/or P2 position of
the inhibitor. The compounds of the present invention can have a
better therapeutic index, owing in part to reduced toxicity and/or
improved specificity for the targeted protease.
Inventors: |
Bachovchin; William W.;
(Cambridge, MA) |
Assignee: |
Trustees of Tufts College
Boston
MA
|
Family ID: |
26988769 |
Appl. No.: |
12/791517 |
Filed: |
June 1, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10496706 |
Oct 22, 2004 |
7727964 |
|
|
PCT/US02/38053 |
Nov 26, 2002 |
|
|
|
12791517 |
|
|
|
|
60333519 |
Nov 26, 2001 |
|
|
|
60405530 |
Aug 23, 2002 |
|
|
|
Current U.S.
Class: |
514/64 ; 435/184;
564/8 |
Current CPC
Class: |
A61K 9/28 20130101; C07D
207/16 20130101; A61P 3/10 20180101; C07F 5/025 20130101; A61P
43/00 20180101; A61P 3/08 20180101; A61P 3/06 20180101; A61K 9/0019
20130101; A61K 31/69 20130101; A61P 3/04 20180101; A61K 45/06
20130101; A61P 9/10 20180101; A61K 9/0053 20130101; A61P 3/00
20180101; A61K 38/28 20130101 |
Class at
Publication: |
514/64 ; 564/8;
435/184 |
International
Class: |
A61K 31/69 20060101
A61K031/69; C07F 5/02 20060101 C07F005/02; C12N 9/99 20060101
C12N009/99; A61P 3/04 20060101 A61P003/04; A61P 3/10 20060101
A61P003/10; A61P 9/10 20060101 A61P009/10 |
Claims
1. A protease inhibitor represented by Formula I: ##STR00040##
wherein A represents a 3-8 membered heterocycle including the N and
the C.alpha. carbon; W represents a functional group which reacts
with an active site residue of the targeted protease to form a
covalent adduct; R.sub.1 represents a hydrogen, a C-terminally
linked amino acid or peptide or analog thereof, or amino protecting
group; R.sub.2 is absent or represents one or more substitutions to
the ring A, each of which can independently be a halogen, a lower
alkyl, a lower alkenyl, a lower alkynyl, a carbonyl, a
thiocarbonyl, an amino, an acylamino, an amido, a cyano, a nitro,
an azido, a sulfate, a sulfonate, a sulfonamido,
--(CH.sub.2).sub.m--R.sub.6, --(CH.sub.2).sub.m--OH,
--(CH.sub.2).sub.m--O-lower alkyl, --(CH.sub.2).sub.m--O-lower
alkenyl, --(CH.sub.2).sub.n--O--(CH.sub.2).sub.m--R.sub.6,
--(CH.sub.2).sub.m--SH, --(CH.sub.2).sub.m--S-lower alkyl,
--(CH.sub.2).sub.m--S-lower alkenyl,
--(CH.sub.2).sub.n--S--(CH.sub.2).sub.m--R.sub.6; R.sub.3a
represents a hydrogen or a substituent which does not conjugate the
electron pair of the nitrogen from which it pends; R.sub.3b is
absent, or represents a substituent which does not conjugate the
electron pair of the nitrogen from which it pends, such as a lower
alkyl; R.sub.4a and R.sub.4b each independently represent a
hydrogen, lower alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl,
aryl, heteroaryl, alkoxyl, carboxyl, carboxamide, carbonyl, or
cyano, with the caveat that either both or neither of R.sub.4a and
R.sub.4b are hydrogen; R.sub.4c represents a halogen, an amine, an
alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl,
alkoxyl, carboxyl, carboxamide, carbonyl, or cyano; R.sub.6
represents, independently for each occurrence, an aryl, aralkyl,
cycloalkyl, cycloalkenyl, or heterocycle moiety; z is zero or an
integer in the range of 1 to 3; m is zero or an integer in the
range of 1 to 8; and n is an integer in the range of 1 to 8.
2. A protease inhibitor represented by Formula III: ##STR00041##
wherein R represents hydrogen, a halogen, or a branched or
unbranched C1-C6 alkyl; W represents a functional group which
reacts with an active site residue of the targeted protease to form
a covalent adduct; R.sub.1 represents a hydrogen, a C-terminally
linked amino acid or peptide or analog thereof, or amino protecting
group; R.sub.3a represents a hydrogen or a substituent which does
not conjugate the electron pair of the nitrogen from which it
pends, such as a lower alkyl; R.sub.3b is absent, or represents a
substituent which does not conjugate the electron pair of the
nitrogen from which it pends, such as a lower alkyl; R.sub.4a, and
R.sub.4b each independently represent a hydrogen, lower alkyl,
heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl,
alkoxyl, carboxyl, carboxamide, carbonyl, or cyano, with the caveat
that either both or neither of R.sub.4a and R.sub.4b are hydrogen;
R.sub.4c represents a halogen, an amine, an alkyl, heteroalkyl,
cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxyl, carboxyl,
carboxamide, carbonyl, or cyano; and z is zero or an integer in the
range of 1 to 3.
3. A protease inhibitor represented by Formula IV: ##STR00042##
wherein A represents a 3-8 membered heterocycle including the N and
the C.alpha. carbon; B represents a C3-C8 ring, or C7-C14 fused
bicyclic or tricyclic ring system; W represents a functional group
which reacts with an active site residue of the targeted protease
to form a covalent adduct; R.sub.1 represents a hydrogen, a
C-terminally linked amino acid or peptide or analog thereof, or
amino protecting group; R.sub.2 is absent or represents one or more
substitutions to the ring A, each of which can independently be a
halogen, a lower alkyl, a lower alkenyl, a lower alkynyl, a
carbonyl, a thiocarbonyl, an amino, an acylamino, an amido, a
cyano, a nitro, an azido, a sulfate, a sulfonate, a sulfonamido,
--(CH.sub.2).sub.m--R.sub.6, --(CH.sub.2).sub.m--OH,
--(CH.sub.2).sub.m--O-lower alkyl, --(CH.sub.2).sub.m--O-lower
alkenyl, --(CH.sub.2).sub.n--O--(CH.sub.2).sub.m--R.sub.6,
--(CH.sub.2).sub.m--SH, --(CH.sub.2).sub.m--S-lower alkyl,
--(CH.sub.2).sub.m--S-lower alkenyl,
--(CH.sub.2).sub.n--S--(CH.sub.2).sub.m--R.sub.6; R.sub.3b is
absent, or represents a substituent which does not conjugate the
electron pair of the nitrogen from which it pends, such as a lower
alkyl; R.sub.6 represents, independently for each occurrence, an
aryl, aralkyl, cycloalkyl, cycloalkenyl, or heterocycle moiety; m
is zero or an integer in the range of 1 to 8; and n is an integer
in the range of 1 to 8.
4. A protease inhibitor represented by Formula VI: ##STR00043##
wherein B represents a C3-C8 ring, or C7-C14 fused bicyclic or
tricyclic ring system; W represents a functional group which reacts
with an active site residue of the targeted protease to form a
covalent adduct; R represents hydrogen, a halogen, or a branched or
unbranched C1-C6 alkyl; R.sub.1 represents a hydrogen, a
C-terminally linked amino acid or peptide or analog thereof, or
amino protecting group; and R.sub.3b is absent, or represents a
substituent which does not conjugate the electron pair of the
nitrogen from which it pends, such as a lower alkyl.
5. The inhibitor of any of claims 1-4, wherein W represents --CN,
--CH.dbd.NR.sub.5, ##STR00044## wherein, Y.sub.1 and Y.sub.2 each
independently represent --OH, or a group capable of being
hydrolyzed to a hydroxyl group, including cyclic derivatives where
Y.sub.1 and Y.sub.2 are connected via a ring having from 5 to 8
atoms in the ring structure; R.sub.5 represents H, an alkyl, an
alkenyl, an alkynyl, --C(X.sub.1)(X.sub.2)X.sub.3,
--(CH.sub.2)m-R.sub.6, --(CH.sub.2)n-OH, --(CH.sub.2)n-O-alkyl,
--(CH.sub.2)n-O-alkenyl, --(CH.sub.2)n-O-alkynyl,
--(CH.sub.2)n-O--(CH.sub.2)m-R.sub.6, --(CH.sub.2)n-SH,
--(CH.sub.2)n-S-alkyl, --(CH.sub.2)n-S-alkenyl,
--(CH.sub.2)n-S-alkynyl, --(CH.sub.2)n-S--(CH.sub.2)m-R.sub.6,
--C(O)C(O)NH.sub.2, --C(O)C(O)OR.sub.7; R.sub.6 represents,
independently for each occurrence, an aryl, aralkyl, cycloalkyl,
cycloalkenyl, or heterocycle moiety; R.sub.7 represents,
independently for each occurrence, hydrogen, or an alkyl, alkenyl,
aryl, aralkyl, cycloalkyl, cycloalkenyl, or heterocycle moiety;
R.sub.50 represents O or S; R.sub.51 represents N.sub.3, SH.sub.2,
NH.sub.2, NO.sub.2 or --OR.sub.7; R.sub.52 represents hydrogen, a
lower alkyl, an amine, --OR.sub.7, or a pharmaceutically acceptable
salt, or R.sub.51 and R.sub.52 taken together with the phosphorous
atom to which they are attached complete a heterocyclic ring having
from 5 to 8 atoms in the ring structure X.sub.1 represents a
halogen; X.sub.2 and X.sub.3 each represent a hydrogen or a
halogen; m is zero or an integer in the range of 1 to 8; and n is
an integer in the range of 1 to 8.
6. The inhibitor of claim 1 or 2, wherein R.sub.4a, R.sub.4b and
R.sub.4c each independently represent a small hydrophobic
group.
7. The inhibitor or claim 6, wherein R.sub.4a, R.sub.4b and
R.sub.4c, are independently selected from the group consisting of
halogens, lower alkyls, lower alkenyls, and lower alkynyls.
8. The inhibitor of claim 1 or 2, wherein R.sub.4a and R.sub.4b
each represent hydrogen, and R.sub.4c represents a small
hydrophobic group.
9. The inhibitor of claim 1, 2 or 5, wherein R.sub.4a and R.sub.4b
each represent hydrogen, and R.sub.4c represents a cycloalkyl,
heterocycloalkyl, aryl, or heteroaryl.
10. The inhibitor of claim 9, wherein R.sub.4c represents a C3-C8
cycloalkyl.
11. The inhibitor of any of claims 1, 3 or 9, wherein R.sub.2 is
absent, or represents --OH.
12. The inhibitor of any of claims 1-6, 9 or 11, wherein R.sub.3a a
hydrogen and R.sub.3b is absent.
13. The inhibitor of any of claims 1-12, wherein W represents:
##STR00045## wherein, Y.sub.1 and Y.sub.2 each independently
represent --OH, or a group capable of being hydrolyzed to a
hydroxyl group, including cyclic derivatives where Y.sub.1 and
Y.sub.2 are connected via a ring having from 5 to 8 atoms in the
ring structure; R.sub.5 represents H, an alkyl, an alkenyl, an
alkynyl, --C(X.sub.1)(X.sub.2)X.sub.3, --(CH.sub.2)m-R.sub.6,
--(CH.sub.2)n-OH, --(CH.sub.2)n-O-alkyl, --(CH.sub.2)n-O-alkenyl,
--(CH.sub.2)n-O-alkynyl, --(CH.sub.2)n-O--(CH.sub.2)m-R.sub.6,
--(CH.sub.2)n-SH, --(CH.sub.2)n-S-alkyl, --(CH.sub.2)n-S-alkenyl,
--(CH.sub.2)n-S-alkynyl, --(CH.sub.2)n-S--(CH.sub.2)m-R.sub.6,
--C(O)C(O)NH.sub.2, --C(O)C(O)OR.sub.7; R.sub.6 represents,
independently for each occurrence, an aryl, aralkyl, cycloalkyl,
cycloalkenyl, or heterocycle moiety; R.sub.7 represents,
independently for each occurrence, hydrogen, or an alkyl, alkenyl,
aryl, aralkyl, cycloalkyl, cycloalkenyl, or heterocycle moiety;
X.sub.1 represents a halogen; X.sub.2 and X.sub.3 each represent a
hydrogen or a halogen; m is zero or an integer in the range of 1 to
8; and n is an integer in the range of 1 to 8.
14. The inhibitor of claim 13, wherein R.sub.5 is a hydrogen or
--C(X.sub.1)(X.sub.2)X.sub.3, wherein X.sub.1 is a fluorine, and
X.sub.2 and X.sub.3, if halogens, are also fluorine.
15. The inhibitor of any of claims 1-12, wherein R.sub.1 is an
amino acid residue or a peptidyl moiety which is a substrate for a
protease.
16. The inhibitor of any of the foregoing claims, wherein the
protease inhibitor inhibits DPIV with a Ki of 50 nm or less.
17. The inhibitor of any of the foregoing claims, which inhibitor
is orally active.
18. A pharmaceutical composition comprising a pharmaceutically
acceptable carrier and a protease inhibitor of any of claims 1-17,
or a pharmaceutically acceptable salt or prodrug thereof.
19. Use of an inhibitor of any of claims 1-17 in the manufacture of
a medicament for inhibiting a post-proline cleaving enzyme in
vivo.
20. The use of claim 19, wherein the inhibitor increases plasma
concentrations of a peptide hormone selected from glucagon like
peptide, NPY, PPY, secretin, GLP-1, GLP-2, and GIP.
21. Use of an inhibitor of any of claims 1-17 in the manufacture of
a medicament for regulating glucose metabolism.
22. The use of claim 21, for regulating glucose metabolism of a
patient suffering from Type II diabetes, insulin resistance,
glucose intolerance, hyperglycemia, hypoglycemia, hyperinsulinemia,
obesity, hyperlipidemia, or hyperlipoproteinemia.
23. A method for inhibiting the proteolytic activity of a
post-proline cleaving enzyme, comprising contacting the enzyme with
a protease inhibitor of any of claims 1-17.
24. A packaged pharmaceutical comprising: a preparation of any of
the protease inhibitor of claims 1-17; a pharmaceutically
acceptable carrier; and instructions, written and/or pictorial,
describing the use of the preparation for inhibiting a post-proline
cleaving enzyme in vivo.
25. A packaged pharmaceutical comprising: a preparation of any of
the protease inhibitor of claims 1-17; a pharmaceutically
acceptable carrier; and instructions, written and/or pictorial,
describing the use of the preparation for regulating glucose
metabolism.
26. The packaged pharmaceutical of claim 25, wherein the protease
inhibitor is co-formulated with, or co-packaged with, insulin
and/or an insulinotropic agent.
27. The packaged pharmaceutical of claim 25, wherein the protease
inhibitor is co-formulated with, or co-packaged with, an M1
receptor antagonist, a prolactin inhibitor, agents acting on the
ATP-dependent potassium channel of n-cells, metformin, and/or
glucosidase inhibitors.
Description
BACKGROUND OF THE INVENTION
[0001] Proteases are enzymes that cleave proteins at single,
specific peptide bonds. Proteases can be classified into four
generic classes: serine, thiol or cysteinyl, acid or aspartyl, and
metalloproteases (Cuypers et al., J. Biol. Chem. 257:7086 (1982)).
Proteases are essential to a variety of biological activities, such
as digestion, formation and dissolution of blood clots,
reproduction and the immune reaction to foreign cells and
organisms. Aberrant proteolysis is associated with a number of
disease states in man and other mammals. In many instances, it is
beneficial to disrupt the function of one or more proteolytic
enzymes in the course of therapeutically treating an animal.
[0002] The binding site for a peptide substrate consists of a
series of "specificity subsites" across the surface of the enzyme.
The term "specificity subsite" refers to a pocket or other site on
the enzyme capable of interacting with a portion of a substrate for
the enzyme. In discussing the interactions of peptides with
proteases, e.g., serine and cysteine proteinases and the like, the
present application utilizes the nomenclature of Schechter and
Berger [(1967) Biochem. Biophys. Res. Commun. 27:157-162)]. The
individual amino acid residues of a substrate or inhibitor are
designated P1, P2, etc. and the corresponding subsites of the
enzyme are designated S1, S2, etc, starting with the carboxy
terminal residue produced in the cleavage reaction. The scissile
bond of the substrate is amide bond between 51-S1' of the
substrate. Thus, for the peptide Xaa1-Xaa2-Xaa3-Xaa4 which is
cleaved between the Xaa3 and Xaa4 residues, the Xaa3 residue is
referred to as the P1 residue and binds to the S1 subsite of the
enzyme, Xaa2 is referred to as the P2 residue and binds to the S2
subsite, and so forth.
[0003] Dipeptidyl peptidase IV (DPIV), for example, is a serine
protease which cleaves N-terminal dipeptides from a peptide chain
containing, preferably, a proline residue in the penultimate
position, e.g., in the P1 position. DPIV belongs to a group of
cell-membrane-associated peptidases and, like the majority of
cell-surface peptidases, is a type II integral membrane protein,
being anchored to the plasma membrane by its signal sequence. DPIV
is found in a variety of differentiated mammalian epithelia,
endothelia and hemapoetic cells and tissues, including those of
lymphoid origin where it is found specifically on the surface of
CD4.sup.+ T cells. DPN has been identified as the leukocyte
differentiation marker CD26.
SUMMARY OF THE INVENTION
[0004] One aspect of the invention provides a protease inhibitor
represented by Formula I:
##STR00001##
wherein
[0005] A represents a 3-8 membered heterocycle including the N and
the C.alpha. carbon;
[0006] W represents a functional group which reacts with an active
site residue of the targeted protease to form a covalent
adduct;
[0007] R.sub.1 represents a hydrogen, a C-terminally linked amino
acid or peptide or analog thereof, or amino protecting group;
[0008] R.sub.2 is absent or represents one or more substitutions to
the ring A, each of which can independently be a halogen, a lower
alkyl, a lower alkenyl, a lower alkynyl, a carbonyl, a
thiocarbonyl, an amino, an acylamino, an amido, a cyano, a nitro,
an azido, a sulfate, a sulfonate, a sulfonamido,
--(CH.sub.2).sub.m--R.sub.6, --(CH.sub.2).sub.m--OH,
--(CH.sub.2).sub.m--O-lower alkyl, --(CH.sub.2).sub.m--O-lower
alkenyl, --(CH.sub.2).sub.n--O--(CH.sub.2).sub.m--R.sub.6,
--(CH.sub.2).sub.m--SH, --(CH.sub.2).sub.m--S-lower alkyl,
--(CH.sub.2).sub.m--S-lower alkenyl,
--(CH.sub.2).sub.n--S--(CH.sub.2).sub.m--R.sub.6;
[0009] R.sub.3a represents a hydrogen or a substituent which does
not conjugate the electron pair of the nitrogen from which it
pends;
[0010] R.sub.3b is absent, or represents a substituent which does
not conjugate the electron pair of the nitrogen from which it
pends, such as a lower alkyl;
[0011] R.sub.4a and R.sub.4b each independently represent a
hydrogen, lower alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl,
aryl, heteroaryl, alkoxyl, carboxyl, carboxamide, carbonyl, or
cyano, with the caveat that either both or neither of R.sub.4a and
R.sub.4b are hydrogen;
[0012] R.sub.4c represents a halogen, an amine, an alkyl,
heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl,
alkoxyl, carboxyl, carboxamide, carbonyl, or cyano;
[0013] R.sub.6 represents, independently for each occurrence, an
aryl, aralkyl, cycloalkyl, cycloalkenyl, or heterocycle moiety;
[0014] z is zero or an integer in the range of 1 to 3; m is zero or
an integer in the range of 1 to 8; and n is an integer in the range
of 1 to 8.
[0015] Another aspect of the invention provides a protease
inhibitor represented by Formula III:
##STR00002##
wherein
[0016] R represents hydrogen, a halogen, or a branched or
unbranched C1-C6 alkyl;
[0017] W represents a functional group which reacts with an active
site residue of the targeted protease to form a covalent
adduct;
[0018] R.sub.1 represents a hydrogen, a C-terminally linked amino
acid or peptide or analog thereof, or amino protecting group;
[0019] R.sub.3a represents a hydrogen or a substituent which does
not conjugate the electron pair of the nitrogen from which it
pends, such as a lower alkyl;
[0020] R.sub.3b is absent, or represents a substituent which does
not conjugate the electron pair of the nitrogen from which it
pends, such as a lower alkyl;
[0021] R.sub.4a and R.sub.4b each independently represent a
hydrogen, lower alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl,
aryl, heteroaryl, alkoxyl, carboxyl, carboxamide, carbonyl, or
cyano, with the caveat that either both or neither of R.sub.4a and
R.sub.4b are hydrogen;
[0022] R.sub.4c represents a halogen, an amine, an alkyl,
heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl,
alkoxyl, carboxyl, carboxamide, carbonyl, or cyano; and
[0023] z is zero or an integer in the range of 1 to 3.
[0024] Yet another aspect of the invention provides a protease
inhibitor represented by Formula IV:
##STR00003##
wherein
[0025] A represents a 3-8 membered heterocycle including the N and
the C.alpha. carbon;
[0026] B represents a C3-C8 ring, or C7-C14 fused bicyclic or
tricyclic ring system;
[0027] W represents a functional group which reacts with an active
site residue of the targeted protease to form a covalent
adduct;
[0028] R.sub.1 represents a hydrogen, a C-terminally linked amino
acid or peptide or analog thereof, or amino protecting group;
[0029] R.sub.2 is absent or represents one or more substitutions to
the ring A, each of which can independently be a halogen, a lower
alkyl, a lower alkenyl, a lower alkynyl, a carbonyl, a
thiocarbonyl, an amino, an acylamino, an amido, a cyano, a nitro,
an azido, a sulfate, a sulfonate, a sulfonamido,
--(CH.sub.2).sub.m--R.sub.6, --(CH.sub.2).sub.m--OH,
--(CH.sub.2).sub.m--O-lower alkyl, --(CH.sub.2).sub.m--O-lower
alkenyl, --(CH.sub.2).sub.n--O--(CH.sub.2).sub.m--R.sub.6,
--(CH.sub.2).sub.m--SH, --(CH.sub.2).sub.m--S-lower alkyl,
--(CH.sub.2).sub.m--S-lower alkenyl,
--(CH.sub.2).sub.n--S--(CH.sub.2).sub.m--R.sub.6;
[0030] R.sub.3b is absent, or represents a substituent which does
not conjugate the electron pair of the nitrogen from which it
pends, such as a lower alkyl;
[0031] R.sub.6 represents, independently for each occurrence, an
aryl, aralkyl, cycloalkyl, cycloalkenyl, or heterocycle moiety;
[0032] m is zero or an integer in the range of 1 to 8; and n is an
integer in the range of 1 to 8.
[0033] Still another aspect of the invention relates to a protease
inhibitor represented by Formula VI:
##STR00004##
wherein
[0034] B represents a C3-C8 ring, or C7-C14 fused bicyclic or
tricyclic ring system;
[0035] W represents a functional group which reacts with an active
site residue of the targeted protease to form a covalent
adduct;
[0036] R represents hydrogen, a halogen, or a branched or
unbranched C1-C6 alkyl;
[0037] R.sub.1 represents a hydrogen, a C-terminally linked amino
acid or peptide or analog thereof, or amino protecting group;
and
[0038] R.sub.3b is absent, or represents a substituent which does
not conjugate the electron pair of the nitrogen from which it
pends, such as a lower alkyl.
[0039] In certain preferred embodiments, the W represents --CN,
--CH.dbd.NR.sub.5,
##STR00005##
wherein,
[0040] Y.sub.1 and Y.sub.2 each independently represent --OH, or a
group capable of being hydrolyzed to a hydroxyl group, including
cyclic derivatives where Y.sub.1 and Y.sub.2 are connected via a
ring having from 5 to 8 atoms in the ring structure;
[0041] R.sub.5 represents H, an alkyl, an alkenyl, an alkynyl,
--C(X.sub.1)(X.sub.2)X.sub.3, --(CH.sub.2).sub.m--R.sub.6,
--(CH.sub.2)n-OH, --(CH.sub.2)n-O-alkyl, --(CH.sub.2)n-O-alkenyl,
--(CH.sub.2)n-O-alkynyl, --(CH.sub.2)n-.beta.-(CH.sub.2)m-R.sub.6,
--(CH.sub.2)n-SH, --(CH.sub.2)n-S-alkyl, --(CH.sub.2)n-S-alkenyl,
--(CH.sub.2)n-S-alkynyl, --(CH.sub.2)n-S--(CH.sub.2)m-R.sub.6,
--C(O)C(O)NH.sub.2, --C(O)C(O)OR.sub.7;
[0042] R.sub.6 represents, independently for each occurrence, an
aryl, aralkyl, cycloalkyl, cycloalkenyl, or heterocycle moiety;
[0043] R.sub.7 represents, independently for each occurrence,
hydrogen, or an alkyl, alkenyl, aryl, aralkyl, cycloalkyl,
cycloalkenyl, or heterocycle moiety;
[0044] R.sub.50 represents O or S;
[0045] R.sub.51 represents N.sub.3, SH.sub.2, NH.sub.2, NO.sub.2 or
--OR.sub.7;
[0046] R.sub.52 represents hydrogen, a lower alkyl, an amine,
--OR.sub.7, or a pharmaceutically acceptable salt, or R.sub.51 and
R.sub.52 taken together with the phosphorous atom to which they are
attached complete a heterocyclic ring having from 5 to 8 atoms in
the ring structure
[0047] X.sub.1 represents a halogen;
[0048] X.sub.2 and X.sub.3 each represent a hydrogen or a
halogen;
[0049] m is zero or an integer in the range of 1 to 8; and n is an
integer in the range of 1 to 8.
[0050] In certain preferred embodiments of the inhibitors, W
represents:
##STR00006##
wherein, Y.sub.1, Y.sub.2, R.sub.5 are as defined above.
[0051] In certain preferred embodiments, W represents
--B(OH).sub.2, or a prodrug thereof which is hydrolyzed to
--B(OH).sub.2 in vivo.
[0052] In certain other preferred embodiments, W represents
--C(.dbd.O)--R.sub.5, wherein R.sub.5 is a hydrogen or
--C(X.sub.1)(X.sub.2)X.sub.3, wherein X.sub.1 is a fluorine, and
X.sub.2 and X.sub.3, if halogens, are also fluorine.
[0053] In certain embodiments of the inhibitors, R.sub.4a, R.sub.4b
and R.sub.4c each independently represent a small hydrophobic
group, such as selected from the group consisting of halogens,
lower alkyls, lower alkenyls, and lower alkynyls.
[0054] In certain embodiments of the inhibitors, R.sub.4a and
R.sub.4b each represent hydrogen, and R.sub.4c represents a small
hydrophobic group.
[0055] In certain embodiments of the inhibitors, R.sub.4a and
R.sub.4b each represent hydrogen, and R.sub.4c represents a
cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, and in certain
preferred embodiments, is a C3-C8 cycloalkyl.
[0056] In certain embodiments of the inhibitors, R.sub.2 is absent,
or represents --OH.
[0057] In certain embodiments of the inhibitors, R.sub.3a a
hydrogen and R.sub.3b is absent.
[0058] In certain embodiments of the inhibitors, R.sub.1 is an
amino acid residue or a peptidyl moiety which is a substrate for a
protease.
[0059] In certain embodiments of the inhibitors, the protease
inhibitor inhibits DPIV with a Ki of 50 nm or less.
[0060] In certain embodiments of the inhibitors, the inhibitor is
orally active.
[0061] In certain embodiments of the inhibitors, the inhibitor has
a therapeudic index in humans of at least 2, and even more
preferably 5, 10 or even 100, e.g., such as a therapeudic index for
regulating glucose metabolism.
[0062] Another aspect of the invention provides a pharmaceutical
composition comprising a pharmaceutically acceptable carrier and
one or more of the subject protease inhibitors, or a
pharmaceutically acceptable salt or prodrug thereof.
[0063] Another aspect of the invention provides for use of one or
more of the subject inhibitors in the manufacture of a medicament
for inhibiting a post-proline cleaving enzyme in vivo. For example,
the subject inhibitors can be used to manufacture medicaments for
increasing plasma concentrations of one or peptide hormones
processed by post-proline cleaving enzymes (e.g., DP-IV and the
like). Exemplary medicaments are useful in increasing plasma
concentrations of such hormones as glucagons-like peptide, NPY,
PPY, secretin, GLP-1, GLP-2, and GIP.
[0064] In certain preferred embodiments, the subject inhibitors can
be used to manufacture medicaments for regulating glucose
metabolism, such as for use in treating patients suffering from
Type II diabetes, insulin resistance, glucose intolerance,
hyperglycemia, hypoglycemia, hyperinsulinemia, obesity,
hyperlipidemia, or hyperlipoproteinemia.
[0065] Yet another aspect of the invention provides a packaged
pharmaceutical comprising: a preparation of one or more of the
subject protease inhibitor; a pharmaceutically acceptable carrier;
and instructions, written and/or pictorial, describing the use of
the preparation for inhibiting a post-proline cleaving enzyme in
vivo, such as for regulating glucose metabolism.
[0066] The packaged pharmaceutical can also include, e.g., as
co-formulation the protease inhibitor or simply co-packaged,
insulin and/or an insulinotropic agent.
[0067] The packaged pharmaceutical can also include, e.g., as
co-formulation the protease inhibitor or simply co-packaged, an M1
receptor antagonist, a prolactin inhibitor, agents acting on the
ATP-dependent potassium channel of .beta.-cells, metformin, and/or
glucosidase inhibitors.
[0068] The present invention also relates to improved methods for
the long-term reduction and abatement of at least one of the
foregoing disorders based on a therapeutic regimen administered
over the short-term.
[0069] The present invention further provides a method for
regulating, and altering on a long-term basis, the glucose and
lipogenic responses of vertebrate animals, including humans.
[0070] In particular, the compounds of the invention may be
employed to provide methods for producing long lasting beneficial
changes in one or more of the following: the sensitivity of the
cellular response of a species to insulin (reduction of insulin
resistance), blood insulin levels, hyperinsulinemia, blood glucose
levels, the amount of body fat stores, blood lipoprotein levels,
and thus to provide effective treatments for diabetes, obesity
and/or atherosclerosis.
BRIEF DESCRIPTION OF THE DRAWINGS
[0071] FIG. 1 is a diagrammatic representation of the synthesis of
a Cyclohexylglycine-boro-Ala.
[0072] FIG. 2 is a blood glucose values curve during oral glucose
challenge test in zucker rats following oral administration of
Cyclohexylglycine-boro-Ala.
[0073] FIG. 3 is a time course of inactivation curve of
His-boro-Ala at pH 8.
[0074] FIG. 4 is a time course of inactivation curve of
Ala-boro-Ala at pH 8.
[0075] FIG. 5 is a time course of inactivation curve of
Phg-boro-Ala at pH 8.
[0076] FIG. 6 is a time course of inactivation curve of
Cyclohexylglycine-boro-Ala at pH 8.
[0077] FIG. 7 is a bar graph illustrating DPPIV enzyme activity as
measured from rat serum samples before and 1 hour after
administration of Cyclohexylglycine-boro-Ala.
[0078] FIG. 8 is a diagrammatic representation of the conformation
equilibrium of Xaa-boro-Alanine compounds.
[0079] FIG. 9 is the UV chromatograph of
t-Butyl-glycine-Pro-nitrile.
[0080] FIG. 10 is a graph showing the DPIV inhibitory activity of
cyclohexylalanine-boroPro,
##STR00007##
[0081] FIG. 11 is a graph showing the DPIV inhibitory activity of
1,2,3,4-tetrahydroisoquinoline-boroProline,
##STR00008##
[0082] FIG. 12 is a graph showing the DPIV inhibitory activity of
1,2,3,4-tetrahydro-beta-carboline-boroProline,
##STR00009##
[0083] FIG. 13 are two graphs, MS and NMR, showing the purification
of Ethylglycine-2-boroThiazolidine,
##STR00010##
[0084] FIG. 14 are two graphs, UV and MS, showing the purification
of Ethylglycine-boroHydroxyproline,
##STR00011##
[0085] FIG. 15 are two graphs, UV and MS, showing the purification
of diaminoglycine-boroProline,
##STR00012##
[0086] FIG. 16 is a graph showing the DPIV inhibitory activity of
Ethylglycine-N(methyl)boroAlanine,
##STR00013##
[0087] FIG. 17 is a graph showing the DPIV inhibitory activity of
Ethylglycine-boroPiperidine,
##STR00014##
[0088] FIG. 18 is an NMR spectra for
Ethylglycine-N(methyl)boroGlycine,
##STR00015##
[0089] FIG. 19 is an NMR spectra for
t-butylglycine-boroAlanine,
##STR00016##
[0090] FIG. 20 is a graph showing the in vivo DPIV inhibitory
activity, at 0.05 mg/kg, of t-butylglycine-boroProline,
##STR00017##
[0091] FIG. 21 is a graph showing the in vivo DPIV inhibitory
activity, at 0.05 mg/kg, of isopropylglycine-boroProline,
##STR00018##
[0092] FIG. 22 is a graph showing the in vivo DPIV inhibitory
activity, at 0.05 mg/kg, of ethylglycine-boroProline,
##STR00019##
[0093] FIG. 23 is a graph showing the in vivo DPIV inhibitory
activity, at 0.05 mg/kg, of (allo)isoleucine-boroProline,
##STR00020##
DETAILED DESCRIPTION
I Overview
[0094] The present invention relates to inhibitors of post-proline
cleaving enzymes, such as inhibitors of dipeptidyl peptidase IV, as
well as pharmaceutical compositions thereof, and methods for using
such inhibitors. In particular, the inhibitors of the present
invention are improved over those in the prior art by selection of
particular classes of sidechains in the P1 and/or P2 position of
the inhibitor. Salient features for compounds of the present
invention include: better therapeutic indices, owing in part to
reduced toxicity and/or improved specificity for the targeted
protease; better oral availability; increased shelf-life; and/or
increased duration of action (such as single oral dosage
formulations which are effective for more than 4 hours, and even
more preferably for more 8, 12 or 16 hours).
[0095] The compounds of the present invention can be used as part
of treatments for a variety of disorders/conditions, such as those
which are mediated by DPIV. For instance, the subject inhibitors
can be used to up-regulate GIP and GLP-1 activities, e.g., by
increasing the half-life of those hormones, as part of a treatment
for regulating glucose levels and/or metabolism, e.g., to reduce
insulin resistance, treat hyperglycemia, hyperinsulinemia, obesity,
hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL
and LDL), and to regulate body fat and more generally lipid stores,
and, more generally, for the improvement of metabolism disorders,
especially those associated with diabetes, obesity and/or
atherosclerosis.
[0096] While not wishing to bound by any particular theory, it is
observed that compounds which inhibit DPIV are, correlatively, able
to improve glucose tolerance (See Examples 2 and 4), though not
necessarily through mechanisms involving DPIV inhibition per se.
Indeed, the applicant has previously demonstrated an effect in mice
lacking a GLP-1 receptor suggesting that the subject method may not
include a mechanism of action directly implicating GLP-1 itself,
though it has not been ruled out that GLP-1 may have other
receptors. However, in light of the correlation with DPIV
inhibition, in preferred embodiments, the subject method utilizes
an agent with a Ki for DPIV inhibition of 50.0 nm or less, more
preferably of 10.0 nm or less, and even more preferably of 1.0, 0.1
or even 0.01 nM or less. Indeed, inhibitors with Ki values in the
picomolar and even femtomolar range are contemplated. Thus, while
the active agents are described herein, for convenience, as "DPIV
inhibitors", it will be understood that such nomenclature is not
intending to limit the subject invention to a particular mechanism
of action.
[0097] Certain of the subject compounds have extended duration.
Accordingly, in certain preferred embodiments, the inhibitor(s) is
selected, and the amount of inhibitor formulated, to provide a
dosage which inhibits serum PPCE (e.g., DPIV) levels by at least 50
percent for at least 4 hours after a single dose, and even more
preferably for at least 8 hours or even 12 or 16 hours after a
single dose.
[0098] For instance, in certain embodiments the method involves
administration of a DPIV inhibitor, preferably at a predetermined
time(s) during a 24-hour period, in an amount effective to improve
one or more aberrant indices associated with glucose metabolism
disorders (e.g., glucose intolerance, insulin resistance,
hyperglycemia, hyperinsulinemia and Type I and II diabetes).
[0099] In other embodiments, the method involves administration of
a DPIV inhibitor in an amount effective to improve aberrant indices
associated with obesity. Fat cells release the hormone leptin,
which travels in the bloodstream to the brain and, through leptin
receptors there, stimulates production of GLP-1. GLP-1, in turn,
produces the sensation of being full. The leading theory is that
the fat cells of most obese people probably produce enough leptin,
but leptin may not be able to properly engage the leptin receptors
in the brain, and so does not stimulate production of GLP-1. There
is accordingly a great deal of research towards utilizing
preparations of GLP-1 as an appetite suppressant. The subject
method provides a means for increasing the half-life of both
endogenous and ectopically added GLP-1 in the treatment of
disorders associated with obesity.
[0100] In a more general sense, the present invention provides
methods and compositions for altering the pharmokinetics of a
variety of different polypeptide hormones by inhibiting the
proteolysis of one or more peptide hormones by DPIV or some other
proteolytic activity. Post-secretory metabolism is an important
element in the overall homeostasis of regulatory peptides, and the
other enzymes involved in these processes may be suitable targets
for pharmacological intervention by the subject method.
[0101] For example, the subject method can be used to increase the
half-life of other proglucagon-derived peptides, such as glicentin
(corresponding to PG 1-69), oxyntomodulin (PG 33-69),
glicentin-related pancreatic polypeptide (GRPP, PG 1-30),
intervening peptide-2 (IP-2, PG 111-122 amide), and glucagon-like
peptide-2 (GLP-2, PG 126-158).
[0102] GLP-2, for example, has been identified as a factor
responsible for inducing proliferation of intestinal epithelium.
See, for example, Drucker et al. (1996) PNAS 93:7911. The subject
method can be used as part of a regimen for treating injury,
inflammation or resection of intestinal tissue, e.g., where
enhanced growth and repair of the intestinal mucosal epithelial is
desired, such as in the treatment of Chron's disease or
Inflammatory Bowel Disease (IBD).
[0103] DPIV has also been implicated in the metabolism and
inactivation of growth hormone-releasing factor (GHRF). GHRF is a
member of the family of homologous peptides that includes glucagon,
secretin, vasoactive intestinal peptide (VIP), peptide histidine
isoleucine (PHI), pituitary adenylate cyclase activating peptide
(PACAP), gastric inhibitory peptide (GIP) and helodermin. Kubiak et
al. (1994) Peptide Res 7:153. GHRF is secreted by the hypothalamus,
and stimulates the release of growth hormone (GH) from the anterior
pituitary. Thus, the subject method can be used to improve clinical
therapy for certain growth hormone deficient children, and in
clinical therapy of adults to improve nutrition and to alter body
composition (muscle vs. fat). The subject method can also be used
in veterinary practice, for example, to develop higher yield milk
production and higher yield, leaner livestock.
[0104] Likewise, the DPIV inhibitors of the subject invention can
be used to alter the plasma half-life of secretin, VIP, PHI, PACAP,
GIP and/or helodermin. Additionally, the subject method can be used
to alter the pharmacokinetics of Peptide YY and neuropeptide Y,
both members of the pancreatic polypeptide family, as DPIV has been
implicated in the processing of those peptides in a manner which
alters receptor selectivity.
[0105] In other embodiments, the subject inhibitors can be used to
stimulate hematopoiesis.
[0106] In still other embodiments, the subject inhibitors can be
used to inhibit growth or vascularization of transformed
cells/tissues, e.g., to inhibit cell proliferation such as that
associated with tumor growth and metastasis, and for inhibiting
angiogenesis in an abnormal proliferative cell mass.
[0107] In yet other embodiments, the subject inhibitors can be used
to reduce immunological responses, e.g., as an
immunosuppressant.
[0108] In yet other examples, the DPIV inhibitors according to the
present invention can be used to treat CNS maladies such as
strokes, tumors, ischemia, Parkinson's disease, memory loss,
hearing loss, vision loss, migraines, brain injury, spinal cord
injury, Alzheimer's disease and amyotrophic lateral sclerosis
(which has a CNS component). Additionally, the DPIV inhibitors can
be used to treat disorders having a more peripheral nature,
including multiplesclerosis and diabetic neuropathy.
[0109] Another aspect of the present invention relates to
pharmaceutical compositions of the subject post-proline cleaving
enzyme inhibitors, particularly DPIV inhibitors, and their uses in
treating and/or preventing disorders which can be improved by
altering the homeostasis of peptide hormones. In a preferred
embodiment, the inhibitors have hypoglycemic and antidiabetic
activities, and can be used in the treatment of disorders marked by
aberrant glucose metabolism (including storage). In particular
embodiments, the compositions of the subject methods are useful as
insulinotropic agents, or to potentiate the insulinotropic effects
of such molecules as GLP-1. In this regard, certain embodiments of
the present compositions can be useful for the treatment and/or
prophylaxis of a variety of disorders, including one or more of:
hyperlipidemia, hyperglycemia, obesity, glucose tolerance
insufficiency, insulin resistance and diabetic complications.
[0110] In general, the inhibitors of the subject method will be
small molecules, e.g., with molecular weights less than 7500 amu,
preferably less than 5000 amu, and even more preferably less than
2000 or even 1000 amu. In preferred embodiments, the inhibitors
will be orally active.
II Definitions
[0111] The term "high affinity" as used herein means strong binding
affinity between molecules with a dissociation constant K.sub.D of
no greater than 1 .mu.M. In a preferred case, the K.sub.D is less
than 100 nM, 10 nM, 1 nM, 100 pM, or even 10 pM or less. In a most
preferred embodiment, the two molecules can be covalently linked
(K.sub.D is essentially 0).
[0112] The term "boro-Ala" refers to the analog of alanine in which
the carboxylate group (COOH) is replaced with a boronyl group
(B(OH).sub.2). Likewise, the term "boro-Pro" refers to the analog
of praline in which the carboxylate group (COOH) is replaced with a
boronyl group (B(OH).sub.2). More generally, the term "boro-Xaa",
where Xaa is an amino acid residue, refers to the analog of an
amino acid in which the carboxylate group (COOH) is replaced with a
boronyl group (B(OH).sub.2).
[0113] A "patient" or "subject" to be treated by the subject method
can mean either a human or non-human subject.
[0114] The term "ED.sub.50" means the dose of a drug that, in 50%
of patients, will provide a clinically relevant improvement or
change in a physiological measurement, such as glucose
responsiveness, increase in hematocrit, decrease in tumor volume,
etc.
[0115] The term "IC50" means the dose of a drug that inhibits a
biological activity by 50%, e.g., the amount of inhibitor required
to inhibit at least 50% of DPIV (or other PPCE) activity in
vivo.
[0116] A compound is said to have an "insulinotropic activity" if
it is able to stimulate, or cause the stimulation of, the synthesis
or expression of the hormone insulin.
[0117] The term "interact" as used herein is meant to include all
interactions (e.g., biochemical, chemical, or biophysical
interactions) between molecules, such as protein-protein,
protein-nucleic acid, nucleic acid-nucleic acid, protein-small
molecule, nucleic acid-small molecule or small molecule-small
molecule interactions.
[0118] The term "LD.sub.50" means the dose of a drug that is lethal
in 50% of test subjects.
[0119] The term "prophylactic or therapeutic" treatment is
art-recognized and includes administration to the host of one or
more of the subject compositions. If it is administered prior to
clinical manifestation of the unwanted condition (e.g., disease or
other unwanted state of the host animal) then the treatment is
prophylactic, i.e., it protects the host against developing the
unwanted condition, whereas if it is administered after
manifestation of the unwanted condition, the treatment is
therapeutic, (i.e., it is intended to diminish, ameliorate, or
stabilize the existing unwanted condition or side effects
thereof).
[0120] The term "preventing" is art-recognized, and when used in
relation to a condition, such as a local recurrence (e.g., pain), a
disease such as cancer, a syndrome complex such as heart failure or
any other medical condition, is well understood in the art, and
includes administration of a composition which reduces the
frequency of, or delays the onset of, symptoms of a medical
condition in a subject relative to a subject which does not receive
the composition. Thus, prevention of cancer includes, for example,
reducing the number of detectable cancerous growths in a population
of patients receiving a prophylactic treatment relative to an
untreated control population, and/or delaying the appearance of
detectable cancerous growths in a treated population versus an
untreated control population, e.g., by a statistically and/or
clinically significant amount. Prevention of an infection includes,
for example, reducing the number of diagnoses of the infection in a
treated population versus an untreated control population, and/or
delaying the onset of symptoms of the infection in a treated
population versus an untreated control population. Prevention of
pain includes, for example, reducing the magnitude of, or
alternatively delaying, pain sensations experienced by subjects in
a treated population versus an untreated control population.
[0121] The term "therapeutic index" refers to the therapeutic index
of a drug defined as LD.sub.50/ED.sub.50.
[0122] A "therapeutically effective amount" of a compound, e.g.,
such as a DPIV inhibitor of the present invention, with respect to
the subject method of treatment, refers to an amount of the
compound(s) in a preparation which, when administered as part of a
desired dosage regimen (to a mammal, preferably a human) alleviates
a symptom, ameliorates a condition, or slows the onset of disease
conditions according to clinically acceptable standards for the
disorder or condition to be treated or the cosmetic purpose, e.g.,
at a reasonable benefit/risk ratio applicable to any medical
treatment.
[0123] A "single oral dosage formulation" is a dosage which
provides an amount of drug to produce a serum concentration at
least as great as the EC50 for that drug, but less than the
LD.sub.50. Another measure for a single oral dosage formulation is
that it provides an amount of drug necessary to produce a serum
concentration at least as great as the IC50 for that drug, but less
than the LD.sub.50. By either measure, a single oral dosage
formulation is preferably an amount of drug which produces a serum
concentration at least 10 percent less than the LD.sub.50, and even
more preferably at least 50 percent, 75 percent or even 90 percent
less than the drug's the LD.sub.50.
[0124] An aliphatic chain comprises the classes of alkyl, alkenyl
and alkynyl defined below. A straight aliphatic chain is limited to
unbranched carbon chain radicals. As used herein, the term
"aliphatic group" refers to a straight chain, branched-chain, or
cyclic aliphatic hydrocarbon group and includes saturated and
unsaturated aliphatic groups, such as an alkyl group, an alkenyl
group, and an alkynyl group.
[0125] Alkyl refers to a fully saturated branched or unbranched
carbon chain radical having the number of carbon atoms specified,
or up to 30 carbon atoms if no specification is made. For example,
alkyl of 1 to 8 carbon atoms refers to radicals such as methyl,
ethyl, propyl, butyl, pentyl, hexyl, heptyl, and octyl, and those
radicals which are positional isomers of these radicals. Alkyl of
10 to 30 carbon atoms includes decyl, undecyl, dodecyl, tridecyl,
tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl,
nonadecyl, eicosyl, heneicosyl, docosyl, tricosyl and tetracosyl.
In preferred embodiments, a straight chain or branched chain alkyl
has 30 or fewer carbon atoms in its backbone (e.g.,
C.sub.1-C.sub.30 for straight chains, C.sub.3-C.sub.30 for branched
chains), and more preferably 20 or fewer. Likewise, preferred
cycloalkyls have from 3-10 carbon atoms in their ring structure,
and more preferably have 5, 6 or 7 carbons in the ring
structure.
[0126] Moreover, the term "alkyl" (or "lower alkyl") as used
throughout the specification, examples, and claims is intended to
include both "unsubstituted alkyls" and "substituted alkyls", the
latter of which refers to alkyl moieties having substituents
replacing a hydrogen on one or more carbons of the hydrocarbon
backbone. Such substituents can include, for example, a halogen, a
hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a
formyl, or an acyl), a thiocarbonyl (such as a thioester, a
thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a
phosphate, a phosphonate, a phosphinate, an amino, an amido, an
amidine, a cyano, a nitro, a sulfhydryl, an alkylthio, a sulfate, a
sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl,
an aralkyl, or an aromatic or heteroaromatic moiety. It will be
understood by those skilled in the art that the moieties
substituted on the hydrocarbon chain can themselves be substituted,
if appropriate. For instance, the substituents of a substituted
alkyl may include substituted and unsubstituted forms of amino,
azido, imino, amido, phosphoryl (including phosphonate and
phosphinate), sulfonyl (including sulfate, sulfonamido, sulfamoyl
and sulfonate), and silyl groups, as well as ethers, alkylthios,
carbonyls (including ketones, aldehydes, carboxylates, and esters),
--CF.sub.3, --CN and the like. Exemplary substituted alkyls are
described below. Cycloalkyls can be further substituted with
alkyls, alkenyls, alkoxyls, alkylthios, aminoalkyls,
carbonyl-substituted alkyls, --CF.sub.3, --CN, and the like.
[0127] Unless the number of carbons is otherwise specified, "lower
alkyl", as used herein, means an alkyl group, as defined above, but
having from one to ten carbons, more preferably from one to six
carbon atoms in its backbone structure such as methyl, ethyl,
n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl.
Likewise, "lower alkenyl" and "lower alkynyl" have similar chain
lengths. Throughout the application, preferred alkyl groups are
lower alkyls. In preferred embodiments, a substituent designated
herein as alkyl is a lower alkyl.
[0128] The term "alkylthio" refers to an alkyl group, as defined
above, having a sulfur radical attached thereto. In preferred
embodiments, the "alkylthio" moiety is represented by one of
--(S)-alkyl, --(S)-alkenyl, --(S)-alkynyl, and
--(S)--(CH.sub.2).sub.m--R.sub.1, wherein m and R.sub.1 are defined
below. Representative alkylthio groups include methylthio,
ethylthio, and the like.
[0129] Alkenyl refers to any branched or unbranched unsaturated
carbon chain radical having the number of carbon atoms specified,
or up to 26 carbon atoms if no limitation on the number of carbon
atoms is specified; and having 1 or more double bonds in the
radical. Alkenyl of 6 to 26 carbon atoms is exemplified by hexenyl,
heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodenyl,
tridecenyl, tetradecenyl, pentadecenyl, hexadecenyl, heptadecenyl,
octadecenyl, nonadecenyl, eicosenyl, heneicosoenyl, docosenyl,
tricosenyl and tetracosenyl, in their various isomeric forms, where
the unsaturated bond(s) can be located anywhere in the radical and
can have either the (Z) or the (E) configuration about the double
bond(s).
[0130] Alkynyl refers to hydrocarbyl radicals of the scope of
alkenyl, but having 1 or more triple bonds in the radical.
[0131] The terms "alkoxyl" or "alkoxy" as used herein refers to an
alkyl group, as defined below, having an oxygen radical attached
thereto. Representative alkoxyl groups include methoxy, ethoxy,
propoxy, tert-butoxy and the like. An "ether" is two hydrocarbons
covalently linked by an oxygen. Accordingly, the substituent of an
alkyl that renders that alkyl an ether is or resembles an alkoxyl,
such as can be represented by one of --O-alkyl, --O-alkenyl,
--O-alkynyl, --O--(CH.sub.2).sub.m--R.sub.1, where m and R.sub.1
are described below.
[0132] The terms "amine" and "amino" are art-recognized and refer
to both unsubstituted and substituted amines, e.g., a moiety that
can be represented by the general formulae:
##STR00021##
wherein R.sub.3, R.sub.5 and R.sub.6 each independently represent a
hydrogen, an alkyl, an alkenyl, --(CH.sub.2).sub.m--R.sub.1, or
R.sub.3 and R.sub.5 taken together with the N atom to which they
are attached complete a heterocycle having from 4 to 8 atoms in the
ring structure; R.sub.1 represents an alkenyl, aryl, cycloalkyl, a
cycloalkenyl, a heterocyclyl or a polycyclyl; and m is zero or an
integer in the range of 1 to 8. In preferred embodiments, only one
of R.sub.3 or R.sub.5 can be a carbonyl, e.g., R.sub.3, R.sub.5 and
the nitrogen together do not form an imide. In even more preferred
embodiments, R.sub.3 and R.sub.5 (and optionally R.sub.6) each
independently represent a hydrogen, an alkyl, an alkenyl, or
--(CH.sub.2).sub.m--R.sub.1. Thus, the term "alkylamine" as used
herein means an amine group, as defined above, having a substituted
or unsubstituted alkyl attached thereto, i.e., at least one of
R.sub.3 and R.sub.5 is an alkyl group. In certain embodiments, an
amino group or an alkylamine is basic, meaning it has a
pK.sub.a>7.00. The protonated forms of these functional groups
have pK.sub.as relative to water above 7.00.
[0133] The term "carbonyl" is art-recognized and includes such
moieties as can be represented by the general formula:
##STR00022##
wherein X is a bond or represents an oxygen or a sulfur, and
R.sub.7 represents a hydrogen, an alkyl, an alkenyl,
--(CH.sub.2).sub.m--R.sub.1 or a pharmaceutically acceptable salt,
R.sub.8 represents a hydrogen, an alkyl, an alkenyl or
--(CH.sub.2).sub.m--R.sub.1, where m and R.sub.1 are as defined
above. Where X is an oxygen and R.sub.7 or R.sub.8 is not hydrogen,
the formula represents an "ester". Where X is an oxygen, and
R.sub.7 is as defined above, the moiety is referred to herein as a
carboxyl group, and particularly when R.sub.7 is a hydrogen, the
formula represents a "carboxylic acid". Where X is an oxygen, and
R.sub.8 is hydrogen, the formula represents a "formate". In
general, where the oxygen atom of the above formula is replaced by
sulfur, the formula represents a "thiocarbonyl" group. Where X is a
sulfur and R.sub.7 or R.sub.8 is not hydrogen, the formula
represents a "thioester" group. Where X is a sulfur and R.sub.7 is
hydrogen, the formula represents a "thiocarboxylic acid" group.
Where X is a sulfur and R.sub.8 is hydrogen, the formula represents
a "thioformate" group. On the other hand, where X is a bond, and
R.sub.7 is not hydrogen, the above formula represents a "ketone"
group. Where X is a bond, and R.sub.7 is hydrogen, the above
formula represents an "aldehyde" group.
[0134] The terms "heterocyclyl" or "heterocyclic group" refer to 3-
to 10-membered ring structures, more preferably 3- to 7-membered
rings, whose ring structures include one to four heteroatoms.
Heterocycles can also be polycycles. Heterocyclyl groups include,
for example, thiophene, thianthrene, furan, pyran, isobenzofuran,
chromene, xanthene, phenoxathiin, pyrrole, imidazole, pyrazole,
isothiazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine,
indolizine, isoindole, indole, indazole, purine, quinolizine,
isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline,
quinazoline, cinnoline, pteridine, carbazole, carboline,
phenanthridine, acridine, pyrimidine, phenanthroline, phenazine,
phenarsazine, phenothiazine, furazan, phenoxazine, pyrrolidine,
oxolane, thiolane, oxazole, piperidine, piperazine, morpholine,
lactones, lactams such as azetidinones and pyrrolidinones, sultams,
sultones, and the like. The heterocyclic ring can be substituted at
one or more positions with such substituents as described above, as
for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl,
hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphate,
phosphonate, phosphinate, carbonyl, carboxyl, silyl, sulfamoyl,
sulfinyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a
heterocyclyl, an aromatic or heteroaromatic moiety, --CF.sub.3,
--CN, or the like.
[0135] As used herein, the term "substituted" is contemplated to
include all permissible substituents of organic compounds. In a
broad aspect, the permissible substituents include acyclic and
cyclic, branched and unbranched, carbocyclic and heterocyclic,
aromatic and nonaromatic substituents of organic compounds.
Illustrative substituents include, for example, those described
herein above. The permissible substituents can be one or more and
the same or different for appropriate organic compounds. For
purposes of this invention, the heteroatoms such as nitrogen may
have hydrogen substituents and/or any permissible substituents of
organic compounds described herein which satisfy the valences of
the heteroatoms. This invention is not intended to be limited in
any manner by the permissible substituents of organic
compounds.
[0136] The term "hydrocarbyl" refers to a monovalent hydrocarbon
radical comprised of carbon chains or rings of up to 26 carbon
atoms to which hydrogen atoms are attached. The term includes
alkyl, cycloalkyl, alkenyl, alkynyl and aryl groups, groups which
have a mixture of saturated and unsaturated bonds, carbocyclic
rings and includes combinations of such groups. It may refer to
straight chain, branched-chain, cyclic structures or combinations
thereof.
[0137] The term "hydrocarbylene" refers to a divalent hydrocarbyl
radical. Representative examples include alkylene, phenylene, or
cyclohexylene. Preferably, the hydrocarbylene chain is fully
saturated and/or has a chain of 1-10 carbon atoms.
[0138] As used herein, the term "nitro" means --NO.sub.2; the term
"halogen" designates --F, --Cl, --Br or --I; the term "sulfhydryl"
means --SH; the term "hydroxyl" means --OH; and the term "sulfonyl"
means --SO.sub.2--.
[0139] It will be understood that "substitution" or "substituted
with" includes the implicit proviso that such substitution is in
accordance with permitted valence of the substituted atom and the
substituent, and that the substitution results in a stable
compound, e.g., which does not spontaneously undergo transformation
such as by rearrangement, cyclization, elimination, etc.
[0140] The term "sulfamoyl" is art-recognized and includes a moiety
that can be represented by the general formula:
##STR00023##
in which R.sub.3 and R.sub.5 are as defined above.
[0141] The term "sulfate" is art recognized and includes a moiety
that can be represented by the general formula:
##STR00024##
in which R.sub.7 is as defined above.
[0142] The term "sulfonamido" is art recognized and includes a
moiety that can be represented by the general formula:
##STR00025##
in which R.sub.2 and R.sub.4 are as defined above.
[0143] The term "sulfonate" is art-recognized and includes a moiety
that can be represented by the general formula:
##STR00026##
in which R.sub.7 is an electron pair, hydrogen, alkyl, cycloalkyl,
or aryl.
[0144] The terms "sulfoxido" or "sulfinyl", as used herein, refers
to a moiety that can be represented by the general formula:
##STR00027##
in which R.sub.12 is selected from the group consisting of
hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl,
aralkyl, or aryl.
[0145] Analogous substitutions can be made to alkenyl and alkynyl
groups to produce, for example, aminoalkenyls, aminoalkynyls,
amidoalkenyls, amidoalkynyls, iminoalkenyls, iminoalkynyls,
thioalkenyls, thioalkynyls, carbonyl-substituted alkenyls or
alkynyls.
[0146] As used herein, the definition of each expression, e.g.,
alkyl, m, n, etc., when it occurs more than once in any structure,
is intended to be independent of its definition elsewhere in the
same structure.
[0147] A "small" substituent is one of 10 atoms or less.
[0148] By the terms "amino acid residue" and "peptide residue" is
meant an amino acid or peptide molecule without the --OH of its
carboxyl group. In general the abbreviations used herein for
designating the amino acids and the protective groups are based on
recommendations of the IUPAC-IUB Commission on Biochemical
Nomenclature (see Biochemistry (1972) 11:1726-1732). For instance
Met, Ile, Leu, Ala and Gly represent "residues" of methionine,
isoleucine, leucine, alanine and glycine, respectively. By the
residue is meant a radical derived from the corresponding
.alpha.-amino acid by eliminating the OH portion of the carboxyl
group and the H portion of the .alpha.-amino group. The term "amino
acid side chain" is that part of an amino acid exclusive of the
--CH(NH.sub.2)COOH portion, as defined by K. D. Kopple, "Peptides
and Amino Acids", W. A. Benjamin Inc., New York and Amsterdam,
1966, pages 2 and 33; examples of such side chains of the common
amino acids are --CH.sub.2CH.sub.2SCH.sub.3 (the side chain of
methionine), --CH.sub.2(CH.sub.3)--CH.sub.2CH.sub.3 (the side chain
of isoleucine), --CH.sub.2CH(CH.sub.3).sub.2 (the side chain of
leucine) or H-(the side chain of glycine).
[0149] For the most part, the amino acids used in the application
of this invention are those naturally occurring amino acids found
in proteins, or the naturally occurring anabolic or catabolic
products of such amino acids which contain amino and carboxyl
groups. Particularly suitable amino acid side chains include side
chains selected from those of the following amino acids: glycine,
alanine, valine, cysteine, leucine, isoleucine, serine, threonine,
methionine, glutamic acid, aspartic acid, glutamine, asparagine,
lysine, arginine, proline, histidine, phenylalanine, tyrosine, and
tryptophan, and those amino acids and amino acid analogs which have
been identified as constituents of peptidylglycan bacterial cell
walls.
[0150] The term amino acid residue further includes analogs,
derivatives and congeners of any specific amino acid referred to
herein, as well as C-terminal or N-terminal protected amino acid
derivatives (e.g. modified with an N-terminal or C-terminal
protecting group). For example, the present invention contemplates
the use of amino acid analogs wherein a side chain is lengthened or
shortened while still providing a carboxyl, amino or other reactive
precursor functional group for cyclization, as well as amino acid
analogs having variant side chains with appropriate functional
groups). For instance, the subject compound can include an amino
acid analog such as, for example, cyanoalanine, canavanine,
djenkolic acid, norleucine, 3-phosphoserine, homoserine,
dihydroxy-phenylalanine, 5-hydroxytryptophan, 1-methylhistidine,
3-methylhistidine, diaminopimelic acid, ornithine, or
diaminobutyric acid. Other naturally occurring amino acid
metabolites or precursors having side chains which are suitable
herein will be recognized by those skilled in the art and are
included in the scope of the present invention.
[0151] Also included are the (D) and (L) stereoisomers of such
amino acids when the structure of the amino acid admits of
stereoisomeric forms. The configuration of the amino acids and
amino acid residues herein are designated by the appropriate
symbols (D), (L) or (DL), furthermore when the configuration is not
designated the amino acid or residue can have the configuration
(D), (L) or (DL). It will be noted that the structure of some of
the compounds of this invention includes asymmetric carbon atoms.
It is to be understood accordingly that the isomers arising from
such asymmetry are included within the scope of this invention.
Such isomers can be obtained in substantially pure form by
classical separation techniques and by sterically controlled
synthesis. For the purposes of this application, unless expressly
noted to the contrary, a named amino acid shall be construed to
include both the (D) or (L) stereoisomers.
[0152] The phrase "protecting group" as used herein means
substituents which protect the reactive functional group from
undesirable chemical reactions. Examples of such protecting groups
include esters of carboxylic acids and boronic acids, ethers of
alcohols and acetals and ketals of aldehydes and ketones. For
instance, the phrase "N-terminal protecting group" or
"amino-protecting group" as used herein refers to various
amino-protecting groups which can be employed to protect the
N-terminus of an amino acid or peptide against undesirable
reactions during synthetic procedures. Examples of suitable groups
include acyl protecting groups such as, to illustrate, formyl,
dansyl, acetyl, benzoyl, trifluoroacetyl, succinyl and
methoxysuccinyl; aromatic urethane protecting groups as, for
example, benzyloxycarbonyl (Cbz); and aliphatic urethane protecting
groups such as t-butoxycarbonyl (Boc) or 9-Fluorenylmethoxycarbonyl
(FMOC).
[0153] As noted above, certain compounds of the present invention
may exist in particular geometric or stereoisomeric forms. The
present invention contemplates all such compounds, including cis-
and trans-isomers, R- and S-enantiomers, diastereomers,
(D)-isomers, (L)-isomers, the racemic mixtures thereof, and other
mixtures thereof, as falling within the scope of the invention.
Additional asymmetric carbon atoms may be present in a substituent
such as an alkyl group. All such isomers, as well as mixtures
thereof, are intended to be included in this invention.
[0154] If, for instance, a particular enantiomer of a compound of
the present invention is desired, it may be prepared by asymmetric
synthesis, or by derivation with a chiral auxiliary, where the
resulting diastereomeric mixture is separated and the auxiliary
group cleaved to provide the pure desired enantiomers.
Alternatively, where the molecule contains a basic functional
group, such as amino, or an acidic functional group, such as
carboxyl, diastereomeric salts are formed with an appropriate
optically-active acid or base, followed by resolution of the
diastereomers thus formed by fractional crystallization or
chromatographic means well known in the art, and subsequent
recovery of the pure enantiomers.
[0155] For purposes of this invention, the chemical elements are
identified in accordance with the Periodic Table of the Elements,
CAS version, Handbook of Chemistry and Physics, 67th Ed., 1986-87,
inside cover. Also for purposes of this invention, the term
"hydrocarbon" is contemplated to include all permissible compounds
having at least one hydrogen and one carbon atom. In a broad
aspect, the permissible hydrocarbons include acyclic and cyclic,
branched and unbranched, carbocyclic and heterocyclic, aromatic and
nonaromatic organic compounds which can be substituted or
unsubstituted.
[0156] A compound is said to have an "insulinotropic activity" if
it is able to stimulate, or cause the stimulation of, the synthesis
or expression of the hormone insulin.
[0157] It will be understood that all generic structures recited
herein, with respect to appropriate combinations of substituents,
are intended to cover those embodiments permitted by valency and
stability.
III Exemplary Embodiments
[0158] (i). Compounds
[0159] One aspect of the present invention is a compound
represented by Formula I:
##STR00028##
[0160] wherein
[0161] A represents a 3-8 membered heterocycle including the N and
the C.alpha. carbon;
[0162] W represents a functional group which reacts with an active
site residue of the targeted protease to form a covalent adduct, as
for example, --CN, --CH.dbd.NR.sub.5,
##STR00029##
[0163] R.sub.1 represents a hydrogen, a C-terminally linked amino
acid or peptide or analog thereof, or amino protecting group;
[0164] R.sub.2 is absent or represents one or more substitutions to
the ring A, each of which can independently be a halogen, a lower
alkyl, a lower alkenyl, a lower alkynyl, a carbonyl (such as a
carboxyl, an ester, a formate, or a ketone), a thiocarbonyl (such
as a thioester, a thioacetate, or a thioformate), an amino, an
acylamino, an amido, a cyano, a nitro, an azido, a sulfate, a
sulfonate, a sulfonamido, --(CH.sub.2).sub.m--R.sub.6,
--(CH.sub.2).sub.m--OH, --(CH.sub.2).sub.m--O-lower alkyl,
--(CH.sub.2).sub.m--O-lower alkenyl,
--(CH.sub.2).sub.n--O--(CH.sub.2).sub.m--R.sub.6,
--(CH.sub.2).sub.m--SH, --(CH.sub.2).sub.m--S-lower alkyl,
--(CH.sub.2).sub.m--S-lower alkenyl,
--(CH.sub.2).sub.n--S--(CH.sub.2).sub.m--R.sub.6;
[0165] R.sub.3a represents a hydrogen or a substituent which does
not conjugate the electron pair of the nitrogen from which it
pends, such as a lower alkyl;
[0166] R.sub.3b is absent, or represents a substituent which does
not conjugate the electron pair of the nitrogen from which it
pends, such as a lower alkyl;
[0167] R.sub.4a and R.sub.4b each independently represent a
hydrogen, lower alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl,
aryl, heteroaryl, alkoxyl, carboxyl, carboxamide, carbonyl, or
cyano, with the caveat that either both or neither of R.sub.4a and
R.sub.4b are hydrogen;
[0168] R.sub.4c represents a halogen, an amine, an alkyl,
heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl,
alkoxyl, carboxyl, carboxamide, carbonyl, or cyano;
[0169] R.sub.5 represents H, an alkyl, an alkenyl, an alkynyl,
--C(X.sub.1)(X.sub.2)X.sub.3, --(CH.sub.2)m-R.sub.6,
--(CH.sub.2)n-OH, --(CH.sub.2)n-O-alkyl, --(CH.sub.2)n-O-alkenyl,
--(CH.sub.2)n-O-alkynyl, --(CH.sub.2)n-O--(CH.sub.2)m-R.sub.6,
--(CH.sub.2)n-SH, --(CH.sub.2)n-S-alkyl, --(CH.sub.2)n-S-alkenyl,
--(CH.sub.2)n-S-alkynyl, --(CH.sub.2)n-S--(CH.sub.2)m-R.sub.6,
--C(O)C(O)NH.sub.2, --C(O)C(O)OR.sub.7;
[0170] R.sub.6 represents, independently for each occurrence, an
aryl, aralkyl, cycloalkyl, cycloalkenyl, or heterocycle moiety;
[0171] R.sub.7 represents, independently for each occurrence,
hydrogen, or an alkyl, alkenyl, aryl, aralkyl, cycloalkyl,
cycloalkenyl, or heterocycle moiety; and
[0172] Y.sub.1 and Y.sub.2 each independently represent --OH, or a
group capable of being hydrolyzed to a hydroxyl group, including
cyclic derivatives where Y.sub.1 and Y.sub.2 are connected via a
ring having from 5 to 8 atoms in the ring structure (such as
pinacol or the like),
[0173] R.sub.50 represents O or S;
[0174] R.sub.51 represents N.sub.3, SH.sub.2, NH.sub.2, NO.sub.2 or
--OR.sub.7;
[0175] R.sub.52 represents hydrogen, a lower alkyl, an amine,
--OR.sub.7, or a pharmaceutically acceptable salt, or R.sub.51 and
R.sub.52 taken together with the phosphorous atom to which they are
attached complete a heterocyclic ring having from 5 to 8 atoms in
the ring structure
[0176] X.sub.1 represents a halogen;
[0177] X.sub.2 and X.sub.3 each represent a hydrogen or a
halogen;
[0178] z is zero or an integer in the range of 1 to 3 (preferably 0
or 1); m is zero or an integer in the range of 1 to 8; and n is an
integer in the range of 1 to 8.
[0179] In certain embodiments, the protease inhibitor is
represented in the general formula
##STR00030##
[0180] where R.sub.1, R.sub.3a, R.sub.3b, R.sub.4a, R.sub.4b,
R.sub.4c and W are as defined above, and p is an integer from 1 to
3. In certain preferred embodiments, p is 1, and R.sub.3a is a
hydrogen and R.sub.3b is absent.
[0181] Another aspect of the present invention is a compound
represented by Formula III:
##STR00031##
[0182] wherein
[0183] R represents hydrogen, a halogen, or a branched or
unbranched C1-C6 alkyl which is unsubstituted or substituted with
one or more of --OH, --SH, --NH.sub.2 or a halogen;
[0184] W represents a functional group which reacts with an active
site residue of the targeted protease to form a covalent adduct, as
for example, --CN, --CH.dbd.NR.sub.5,
##STR00032##
[0185] R.sub.1 represents a hydrogen, a C-terminally linked amino
acid or peptide or analog thereof, or amino protecting group;
[0186] R.sub.3a represents a hydrogen or a substituent which does
not conjugate the electron pair of the nitrogen from which it
pends, such as a lower alkyl;
[0187] R.sub.3b is absent, or represents a substituent which does
not conjugate the electron pair of the nitrogen from which it
pends, such as a lower alkyl;
[0188] R.sub.4a and R.sub.4b each independently represent a
hydrogen, lower alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl,
aryl, heteroaryl, alkoxyl, carboxyl, carboxamide, carbonyl, or
cyano, with the caveat that either both or neither of R.sub.4a and
R.sub.4b are hydrogen;
[0189] R.sub.4c represents a halogen, an amine, an alkyl,
heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl,
alkoxyl, carboxyl, carboxamide, carbonyl, or cyano;
[0190] R.sub.5 represents H, an alkyl, an alkenyl, an alkynyl,
--C(X.sub.1)(X.sub.2)X.sub.3, --(CH.sub.2)m-R.sub.6,
--(CH.sub.2)n-OH, --(CH.sub.2)n-O-alkyl, --(CH.sub.2)n-O-alkenyl,
--(CH.sub.2)n-O-alkynyl, --(CH.sub.2)n-O --(CH.sub.2)m-R.sub.6,
--(CH.sub.2)n-SH, --(CH.sub.2)n-S-alkyl, --(CH.sub.2)n-S-alkenyl,
--(CH.sub.2)n-S-alkynyl, --(CH.sub.2)n-S--(CH.sub.2)m-R.sub.6,
--C(O)C(O)NH.sub.2, --C(O)C(O)OR.sub.7;
[0191] R.sub.6 represents, independently for each occurrence, an
aryl, aralkyl, cycloalkyl, cycloalkenyl, or heterocycle moiety;
[0192] R.sub.7 represents, independently for each occurrence,
hydrogen, or an alkyl, alkenyl, aryl, aralkyl, cycloalkyl,
cycloalkenyl, or heterocycle moiety; and
[0193] Y.sub.1 and Y.sub.2 each independently represent --OH, or a
group capable of being hydrolyzed to a hydroxyl group, including
cyclic derivatives where Y.sub.1 and Y.sub.2 are connected via a
ring having from 5 to 8 atoms in the ring structure (such as
pinacol or the like),
[0194] R.sub.50 represents O or S;
[0195] R.sub.51 represents N.sub.3, SH.sub.2, NH.sub.2, NO.sub.2 or
--OR.sub.7;
[0196] R.sub.52 represents hydrogen, a lower alkyl, an amine,
--OR.sub.7, or a pharmaceutically acceptable salt, or R.sub.51 and
R.sub.52 taken together with the phosphorous atom to which they are
attached complete a heterocyclic ring having from 5 to 8 atoms in
the ring structure
[0197] X.sub.1 represents a halogen;
[0198] X.sub.2 and X.sub.3 each represent a hydrogen or a
halogen;
[0199] z is zero or an integer in the range of 1 to 3 (preferably 0
or 1); m is zero or an integer in the range of 1 to 8; and n is an
integer in the range of 1 to 8.
[0200] Yet another aspect of the present invention provides a
compound represented by Formula IV:
##STR00033##
[0201] wherein
[0202] A represents a 3-8 membered heterocycle including the N and
the C.alpha. carbon;
[0203] B represents a C3-C8 ring, or C7-C14 fused bicyclic or
tricyclic ring system;
[0204] W represents a functional group which reacts with an active
site residue of the targeted protease to form a covalent adduct, as
for example, --CN, --CH.dbd.NR.sub.5,
##STR00034##
[0205] R.sub.1 represents a hydrogen, a C-terminally linked amino
acid or peptide or analog thereof, or amino protecting group;
[0206] R.sub.2 is absent or represents one or more substitutions to
the ring A, each of which can independently be a halogen, a lower
alkyl, a lower alkenyl, a lower alkynyl, a carbonyl (such as a
carboxyl, an ester, a formate, or a ketone), a thiocarbonyl (such
as a thioester, a thioacetate, or a thioformate), an amino, an
acylamino, an amido, a cyano, a nitro, an azido, a sulfate, a
sulfonate, a sulfonamido, --(CH.sub.2).sub.m--R.sub.6,
--(CH.sub.2).sub.m--OH, --(CH.sub.2).sub.m--O-lower alkyl,
--(CH.sub.2).sub.m--O-lower alkenyl,
--(CH.sub.2).sub.n--O--(CH.sub.2).sub.m--R.sub.6,
--(CH.sub.2).sub.m--SH, --(CH.sub.2).sub.m--S-lower alkyl,
--(CH.sub.2).sub.m--S-lower alkenyl,
--(CH.sub.2).sub.n--S--(CH.sub.2).sub.m--R.sub.6;
[0207] R.sub.3b is absent, or represents a substituent which does
not conjugate the electron pair of the nitrogen from which it
pends, such as a lower alkyl;
[0208] R.sub.5 represents H, an alkyl, an alkenyl, an alkynyl,
--C(X.sub.1)(X.sub.2)X.sub.3, --(CH.sub.2).sub.m--R.sub.6,
--(CH.sub.2)n-OH, --(CH.sub.2)n-O-alkyl, --(CH.sub.2)n-O-alkenyl,
--(CH.sub.2)n-O-alkynyl, --(CH.sub.2)n-O
--(CH.sub.2).sub.m--R.sub.6, --(CH.sub.2)n-SH,
--(CH.sub.2)n-S-alkyl, --(CH.sub.2)n-S-alkenyl,
--(CH.sub.2)n-S-alkynyl, --(CH.sub.2)n-S--(CH.sub.2)m-R.sub.6,
--C(O)C(O)NH.sub.2, --C(O)C(O)OR.sub.7;
[0209] R.sub.6 represents, independently for each occurrence, an
aryl, aralkyl, cycloalkyl, cycloalkenyl, or heterocycle moiety;
[0210] R.sub.7 represents, independently for each occurrence,
hydrogen, or an alkyl, alkenyl, aryl, aralkyl, cycloalkyl,
cycloalkenyl, or heterocycle moiety; and
[0211] Y.sub.1 and Y.sub.2 each independently represent --OH, or a
group capable of being hydrolyzed to a hydroxyl group, including
cyclic derivatives where Y.sub.1 and Y.sub.2 are connected via a
ring having from 5 to 8 atoms in the ring structure (such as
pinacol or the like),
[0212] R.sub.50 represents O or S;
[0213] R.sub.51 represents N.sub.3, SH.sub.2, NH.sub.2, NO.sub.2 or
--OR.sub.7;
[0214] R.sub.52 represents hydrogen, a lower alkyl, an amine,
--OR.sub.7, or a pharmaceutically acceptable salt, or R.sub.51 and
R.sub.52 taken together with the phosphorous atom to which they are
attached complete a heterocyclic ring having from 5 to 8 atoms in
the ring structure
[0215] X.sub.1 represents a halogen;
[0216] X.sub.2 and X.sub.3 each represent a hydrogen or a
halogen;
[0217] m is zero or an integer in the range of 1 to 8; and n is an
integer in the range of 1 to 8.
[0218] In certain embodiments, the protease inhibitor is
represented in the general formula V:
##STR00035##
[0219] where B, R.sub.1, R.sub.3b and W are as defined above, and p
is an integer from 1 to 3. In certain preferred embodiments, p is
1, and R.sub.3a is a hydrogen and R.sub.3b is absent.
[0220] Another aspect of the present invention is a compound
represented by Formula VI:
##STR00036##
[0221] R represents hydrogen, a halogen, or a branched or
unbranched C1-C6 alkyl which is unsubstituted or substituted with
one or more of --OH, --SH, --NH.sub.2 or a halogen;
[0222] B represents a C3-C8 ring, or C7-C14 fused bicyclic or
tricyclic ring system;
[0223] W represents a functional group which reacts with an active
site residue of the targeted protease to form a covalent adduct, as
for example, --CN, --CH.dbd.NR.sub.5,
##STR00037##
[0224] R.sub.1 represents a hydrogen, a C-terminally linked amino
acid or peptide or analog thereof, or amino protecting group;
[0225] R.sub.3b is absent, or represents a substituent which does
not conjugate the electron pair of the nitrogen from which it
pends, such as a lower alkyl;
[0226] R.sub.5 represents H, an alkyl, an alkenyl, an alkynyl,
--C(X.sub.1)(X.sub.2)X.sub.3, --(CH.sub.2)m-R.sub.6,
--(CH.sub.2)n-OH, --(CH.sub.2)n-O-alkyl, --(CH.sub.2)n-O-alkenyl,
--(CH.sub.2)n-O-alkynyl, --(CH.sub.2)n-O --(CH.sub.2)m-R.sub.6,
--(CH.sub.2)n-SH, --(CH.sub.2)n-S-alkyl, --(CH.sub.2)n-S-alkenyl,
--(CH.sub.2)n-S-alkynyl, --(CH.sub.2)n-S--(CH.sub.2)m-R.sub.6,
--C(O)C(O)NH.sub.2, --C(O)C(O)OR.sub.7;
[0227] R.sub.6 represents, independently for each occurrence, an
aryl, aralkyl, cycloalkyl, cycloalkenyl, or heterocycle moiety;
[0228] R.sub.7 represents, independently for each occurrence,
hydrogen, or an alkyl, alkenyl, aryl, aralkyl, cycloalkyl,
cycloalkenyl, or heterocycle moiety; and
[0229] Y.sub.1 and Y.sub.2 each independently represent --OH, or a
group capable of being hydrolyzed to a hydroxyl group, including
cyclic derivatives where Y.sub.1 and Y.sub.2 are connected via a
ring having from 5 to 8 atoms in the ring structure (such as
pinacol or the like),
[0230] R.sub.50 represents O or S;
[0231] R.sub.51 represents N.sub.3, SH.sub.2, NH.sub.2, NO.sub.2 or
--OR.sub.7;
[0232] R.sub.52 represents hydrogen, a lower alkyl, an amine,
--OR.sub.7, or a pharmaceutically acceptable salt, or R.sub.51 and
R.sub.52 taken together with the phosphorous atom to which they are
attached complete a heterocyclic ring having from 5 to 8 atoms in
the ring structure
[0233] X.sub.1 represents a halogen;
[0234] X.sub.2 and X.sub.3 each represent a hydrogen or a
halogen;
[0235] m is zero or an integer in the range of 1 to 8; and n is an
integer in the range of 1 to 8.
[0236] In certain preferred embodiments of the subject inhibitor
structures above, W represents:
##STR00038##
[0237] In certain preferred embodiments of the subject inhibitor
structures above, R.sub.5 is a hydrogen or
--C(X.sub.1)(X.sub.2)X.sub.3, wherein X.sub.1 is a fluorine, and
X.sub.2 and X.sub.3, if halogens, are also fluorine.
[0238] In certain preferred embodiments of the subject inhibitor
structures above, R.sub.1 is a peptidyl moiety which is a substrate
for a protease which cleaves between R.sub.1 and its pendent amine
moiety. In other preferred embodiments, R.sub.1 is an amino
blocking group.
[0239] In certain preferred embodiments, A is a 4-8 membered ring,
more preferably a 5, 6 or 7 membered ring. A can be a ring selected
from the group consisting of azaridines, thiazoles, pyrroles,
diazoles (such as imidazoles and pyrazolidines), pyridines,
oxazoles, isozazoles, isothiazoles, azepines, diazepines,
oxadiazoles, oxatriazoles, dioxazoles, oxathiazoles, pyrimidines,
pyridazines, pyranzines, triazines, oxazines, isoxzaines, and
oxathiazines, or reduced forms thereof (e.g., dihydro- and
tetrahydro-versions thereof), such pyrrolidines, piperidines,
piperazines, morpholines, thiazolidines, and imidazolines. In
certain preferred embodiments, A is a thiazole, pyrrole, or
pyridine, or reduced form thereof.
[0240] In certain preferred embodiments, R represents hydrogen or a
branched or unbranched C1-C6 alkyl;
[0241] In certain preferred embodiments, R.sub.2 is absent. In
other preferred embodiments, R.sub.2 represents one or two,
preferably one, hydroxyl group.
[0242] In certain preferred embodiments, R.sub.3a and R.sub.3b each
independently represent hydrogen. In other preferred embodiments,
R.sub.3a and R.sub.3b each independently represent hydrogen or a
C1-C3 alkyl.
[0243] In certain preferred embodiments, each of R.sub.4a and
R.sub.4b each independently represent (subject to the above
proviso) hydrogen or a small hydrophobic group such as a halogen, a
lower alkyl, a lower alkenyl, or a lower alkynyl; and R.sub.4c
represents a halogen, a lower alkyl, a lower alkenyl, or a lower
alkynyl. In certain preferred embodiments, R.sub.4a is a hydrogen,
and R.sub.4b and R.sub.4c are both C1-4 alkyls, or R.sub.4a,
R.sub.4b and R.sub.4c are all C1-4 alkyls.
[0244] In certain preferred embodiments, R.sub.4a and R.sub.4b are
both hydrogen, and R.sub.4c represents a cycloalkyl, a
heterocycloalkyl, an aryl or heteroaryl group, such as a 3-8
membered ring, more preferably a 5, 6 or 7 membered ring. The ring
may be substituted by up to 4 heteroatoms--selected from the group
consisting of 0 (oxygen), S (sulphur) or N (nitrogen). In certain
preferred embodiments, R.sub.4c is a cycloalkyl.
[0245] In certain embodiments, B is 3-8 membered ring, more
preferably a 5, 6 or 7 membered ring. B can be a ring selected from
the group consisting of azaridines, thiazoles, pyrroles, diazoles
(such as imidazoles and pyrazolidines), pyridines, oxazoles,
isozazoles, isothiazoles, azepines, diazepines, oxadiazoles,
oxatriazoles, dioxazoles, oxathiazoles, pyrimidines, pyridazines,
pyranzines, triazines, oxazines, isoxzaines, and oxathiazines, or
reduced forms thereof (e.g., dihydro- and tetrahydro-versions
thereof), such pyrrolidines, piperidines, piperazines, morpholines,
thiazolidines, and imidazolines.
[0246] In certain embodiments, B is a bicyclic or tricyclic ring
such as an indole, an indolenine, an isobenzazole, a pyrindine, a
pyrannopyrrole, an isoindazole, an indoxazine, a benzoxazole, an
anthanil, a quinoline, an isoquinoline, a cinnoline, a quinazoline,
a napthyridine, a pyridopyridine, a benzoxazine, a benzisoxazine, a
carbazole, an acridine, or a purine, or reduced forms thereof
(e.g., dihydro- and tetrahydro-versions thereof). In certain
preferred embodiments, B is a tetrahydroisoquinoline or a
tetrahydrocarboline (such as a .beta. or .gamma.-carboline).
[0247] In certain embodiments, B is unsubstituted, or is
substituted with one or more of --OH, --SH, --NH.sub.2, halogens,
or lower alkyl. In certain preferred embodiments, B is
unsubstituted.
[0248] In certain embodiments, B is 3-8 membered ring, more
preferably a 5, 6 or 7 membered ring. B can be a ring selected from
the group consisting of azaridines, thiazoles, pyrroles, diazoles
(such as imidazoles and pyrazolidines), pyridines, oxazoles,
isozazoles, isothiazoles, azepines, diazepines, oxadiazoles,
oxatriazoles, dioxazoles, oxathiazoles, pyrimidines, pyridazines,
pyranzines, triazines, oxazines, isoxzaines, and oxathiazines, or
reduced forms thereof (e.g., dihydro- and tetrahydro-versions
thereof), such pyrrolidines, piperidines, piperazines, morpholines,
thiazolidines, and imidazolines.
[0249] In certain embodiments, B is a bicyclic or tricyclic ring
such as an indole, an indolenine, an isobenzazole, a pyrindine, a
pyrannopyrrole, an isoindazole, an indoxazine, a benzoxazole, an
anthanil, a quinoline, an isoquinoline, a cinnoline, a quinazoline,
a napthyridine, a pyridopyridine, a benzoxazine, a benzisoxazine, a
carbazole, an acridine, or a purine, or reduced forms thereof
(e.g., dihydro- and tetrahydro-versions thereof). In certain
preferred embodiments, B is a tetrahydroisoquinoline or a
tetrahydrocarboline (such as a .beta. or .gamma.-carboline).
[0250] In certain preferred embodiments, if A represents a
pyrrolidine ring, then R.sub.4a, R.sub.4b and R.sub.4c, are
selected such that they do not give rise to a naturally occurring
amino acid side chain, e.g., as defined by the IUPAC-IUB Commission
on Biochemical Nomenclature.
[0251] In certain preferred embodiments, if R.sub.4a, R.sub.4b and
R.sub.4c are selected to give rise to a naturally occurring amino
acid side chain, e.g., as defined by the IUPAC-IUB Commission on
Biochemical Nomenclature, then A is not a pyrrolidine ring.
[0252] In certain preferred embodiments, z is zero or 1.
[0253] Exemplary structures include compounds include.
##STR00039##
[0254] In certain preferred embodiments, the subject inhibitors are
DPIV inhibitors with a Ki for DPIV inhibition of 10 nm or less,
more preferably of 1.0 nm or less, and even more preferably of 0.1
or even 0.01 nM or less. Indeed, inhibitors with Ki values in the
picomolar and even femtomolar range are contemplated.
[0255] In general, the inhibitors of the subject method will be
small molecules, e.g., with molecular weights less than 7500 amu,
preferably less than 5000 amu, and even more preferably less than
2000 amu and even 1000 amu. In preferred embodiments, the
inhibitors will be orally active.
[0256] Another aspect of the present invention relates to
pharmaceutical compositions of dipeptidylpeptidase inhibitors,
particularly inhibitor(s), and their uses in treating and/or
preventing disorders which can be improved by altering the
homeostasis of peptide hormones. In a preferred embodiment, the
inhibitors have hypoglycemic and antidiabetic activities, and can
be used in the treatment of disorders marked by abberrant glucose
metabolism (including storage). In particular embodiments, the
compositions of the subject methods are useful as insulinotropic
agents, or to potentiate the insulinotropic effects of such
molecules as GLP-1. In this regard, the present method can be
useful for the treatment and/or prophylaxis of a variety of
disorders, including one or more of: hyperlipemia, hyperglycemia,
obesity, glucose tolerance insufficiency, insulin resistance and
diabetic complications.
[0257] For instance, in certain embodiments the method involves
administration of an inhibitor(s), preferably at a predetermined
time(s) during a 24-hour period, in an amount effective to improve
one or more aberrant indices associated with glucose metabolism
disorders (e.g., glucose intolerance, insulin resistance,
hyperglycemia, hyperinsulinemia and Type II diabetes). The
effective amount of the inhibitor may be about 0.01, 0.1, 1, 10,
30, 50, 70, 100, 150, 200, 500, or 1000 mg/kg of the subject.
[0258] (ii). Agonism of GLP-1 Effects
[0259] The inhibitors useful in the subject methods possess, in
certain embodiments, the ability to lower blood glucose levels, to
relieve obesity, to alleviate impaired glucose tolerance, to
inhibit hepatic glucose neogenesis, and to lower blood lipid levels
and to inhibit aldose reductase. They are thus useful for the
prevention and/or therapy of hyperglycemia, obesity,
hyperlipidemia, diabetic complications (including retinopathy,
nephropathy, neuropathy, cataracts, coronary artery disease and
arteriosclerosis) and furthermore for obesity-related hypertension
and osteoporosis.
[0260] Diabetes mellitus is a disease characterized by
hyperglycemia occurring from a relative or absolute decrease in
insulin secretion, decreased insulin sensitivity or insulin
resistance. The morbidity and mortality of this disease result from
vascular, renal, and neurological complications. An oral glucose
tolerance test is a clinical test used to diagnose diabetes. In an
oral glucose tolerance test, a patient's physiological response to
a glucose load or challenge is evaluated. After ingesting the
glucose, the patient's physiological response to the glucose
challenge is evaluated. Generally, this is accomplished by
determining the patient's blood glucose levels (the concentration
of glucose in the patient's plasma, serum or whole blood) for
several predetermined points in time.
[0261] In one embodiment, the present invention provides a method
for agonizing the action of GLP-1. It has been determined that
isoforms of GLP-1(GLP-1(7-37) and GLP-1(7-36)), which are derived
from preproglucagon in the intestine and the hind brain, have
insulinotropic activity, i.e., they modulate glucose metabolism.
DPIV cleaves the isoforms to inactive peptides. Thus, in certain
embodiments, inhibitor(s) of the present invention can agonize
insulinotropic activity by interfering with the degradation of
bioactive GLP-1 peptides.
[0262] (iii). Agonism of the Effects of Other Peptide Homones
[0263] In another embodiment, the subject agents can be used to
agonize (e.g., mimic or potentiate) the activity of peptide
hormones, e.g., GLP-2, GIP and NPY.
[0264] To illustrate further, the present invention provides a
method for agonizing the action of GLP-2. It has been determined
that GLP-2 acts as a trophic agent, to promote growth of
gastrointestinal tissue. The effect of GLP-2 is marked particularly
by increased growth of the small bowel, and is therefore herein
referred to as an "intestinotrophic" effect. DPIV is known to
cleave GLP-2 into a biologically inactive peptide. Thus, in one
embodiment, inhibition of DPIV interferes with the degradation of
GLP-2, and thereby increases the plasma half-life of that
hormone.
[0265] In still other embodiments, the subject method can be used
to increase the half-life of other proglucagon-derived peptides,
such as glicentin, oxyntomodulin, glicentin-related pancreatic
polypeptide (GRPP), and/or intervening peptide-2 (IP-2). For
example, glicentin has been demonstrated to cause proliferation of
intestinal mucosa and also inhibits a peristalsis of the stomach,
and has thus been elucidated as useful as a therapeutic agent for
digestive tract diseases, thus leading to the present
invention.
[0266] Thus, in one aspect, the present invention relates to
therapeutic and related uses of inhibitor(s) for promoting the
growth and proliferation of gastrointestinal tissue, most
particularly small bowel tissue. For instance, the subject method
can be used as part of a regimen for treating injury, inflammation
or resection of intestinal tissue, e.g., where enhanced growth and
repair of the intestinal mucosal epithelial is desired.
[0267] With respect to small bowel tissue, such growth is measured
conveniently as a increase in small bowel mass and length, relative
to an untreated control. The effect of subject inhibitors on small
bowel also manifests as an increase in the height of the crypt plus
villus axis. Such activity is referred to herein as an
"intestinotrophic" activity. The efficacy of the subject method may
also be detectable as an increase in crypt cell proliferation
and/or a decrease in small bowel epithelium apoptosis. These
cellular effects may be noted most significantly in relation to the
jejunum, including the distal jejunum and particularly the proximal
jejunum, and also in the distal ileum. A compound is considered to
have "intestinotrophic effect" if a test animal exhibits
significantly increased small bowel weight, increased height of the
crypt plus villus axis, or increased crypt cell proliferation or
decreased small bowel epithelium apoptosis when treated with the
compound (or genetically engineered to express it themselves). A
model suitable for determining such gastrointestinal growth is
described by U.S. Pat. No. 5,834,428.
[0268] In general, patients who would benefit from either increased
small intestinal mass and consequent increased small bowel mucosal
function are candidates for treatment by the subject method.
Particular conditions that may be treated include the various forms
of sprue including celiac sprue which results from a toxic reaction
to .quadrature.-gliadin from wheat, and is marked by a tremendous
loss of villae of the bowel; tropical sprue which results from
infection and is marked by partial flattening of the villae;
hypogammaglobulinemic sprue which is observed commonly in patients
with common variable immunodeficiency or hypogammaglobulinemia and
is marked by significant decrease in villus height. The therapeutic
efficacy of the treatment may be monitored by enteric biopsy to
examine the villus morphology, by biochemical assessment of
nutrient absorption, by patient weight gain, or by amelioration of
the symptoms associated with these conditions. Other conditions
that may be treated by the subject method, or for which the subject
method may be useful prophylactically, include radiation enteritis,
infectious or post-infectious enteritis, regional enteritis
(Crohn's disease), small intestinal damage due to toxic or other
chemotherapeutic agents, and patients with short bowel
syndrome.
[0269] More generally, the present invention provides a therapeutic
method for treating digestive tract diseases. The term "digestive
tract" as used herein means a tube through which food passes,
including stomach and intestine. The term "digestive tract
diseases" as used herein means diseases accompanied by a
qualitative or quantitative abnormality in the digestive tract
mucosa, which include, e.g., ulceric or inflammatory disease;
congenital or acquired digestion and absorption disorder including
malabsorption syndrome; disease caused by loss of a mucosal barrier
function of the gut; and protein-losing gastroenteropathy. The
ulceric disease includes, e.g., gastric ulcer, duodenal ulcer,
small intestinal ulcer, colonic ulcer and rectal ulcer. The
inflammatory disease include, e.g., esophagitis, gastritis,
duodenitis, enteritis, colitis, Crohn's disease, proctitis,
gastrointestinal Behcet, radiation enteritis, radiation colitis,
radiation proctitis, enteritis and medicamentosa. The malabsorption
syndrome includes the essential malabsorption syndrome such as
disaccharide-decomposing enzyme deficiency, glucose-galactose
malabsorption, fractose malabsorption; secondary malabsorption
syndrome, e.g., the disorder caused by a mucosal atrophy in the
digestive tract through the intravenous or parenteral nutrition or
elemental diet, the disease caused by the resection and shunt of
the small intestine such as short gut syndrome, cul-de-sac
syndrome; and indigestible malabsorption syndrome such as the
disease caused by resection of the stomach, e.g., dumping
syndrome.
[0270] The term "therapeutic agent for digestive tract diseases" as
used herein means the agents for the prevention and treatment of
the digestive tract diseases, which include, e.g., the therapeutic
agent for digestive tract ulcer, the therapeutic agent for
inflammatory digestive tract disease, the therapeutic agent for
mucosal atrophy in the digestive tract and the therapeutic agent
for digestive tract wound, the amelioration agent for the function
of the digestive tract including the agent for recovery of the
mucosal barrier function and the amelioration agent for digestive
and absorptive function. The ulcers include digestive ulcers and
erosions, acute ulcers, namely, acute mucosal lesions.
[0271] The subject method, because of promoting proliferation of
intestinal mucosa, can be used in the treatment and prevention of
pathologic conditions of insufficiency in digestion and absorption,
that is, treatment and prevention of mucosal atrophy, or treatment
of hypoplasia of the digestive tract tissues and decrease in these
tissues by surgical removal as well as improvement of digestion and
absorption. Further, the subject method can be used in the
treatment of pathologic mucosal conditions due to inflammatory
diseases such as enteritis, Crohn's disease and ulceric colitis and
also in the treatment of reduction in function of the digestive
tract after operation, for example, in damping syndrome as well as
in the treatment of duodenal ulcer in conjunction with the
inhibition of peristalsis of the stomach and rapid migration of
food from the stomach to the jejunum. Furthermore, glicentin can
effectively be used in promoting cure of surgical invasion as well
as in improving functions of the digestive tract. Thus, the present
invention also provides a therapeutic agent for atrophy of the
digestive tract mucosa, a therapeutic agent for wounds in the
digestive tract and a drug for improving functions of the digestive
tract which comprise glicentin as active ingredients.
[0272] Likewise, the inhibitor(s) of the subject invention can be
used to alter the plasma half-life of secretin, VIP, PHI, PACAP,
GIP and/or helodermin. Additionally, the subject method can be used
to alter the pharmacokinetics of Peptide YY and neuropeptide Y,
both members of the pancreatic polypeptide family, as DPIV has been
implicated in the processing of those peptides in a manner which
alters receptor selectivity.
[0273] Neuropeptide Y (NPY) is believed to act in the regulation
vascular smooth muscle tone, as well as regulation of blood
pressure. NPY also decreases cardiac contractility. NPY is also the
most powerful appetite stimulant known (Wilding et al., (1992) J
Endocrinology 132:299-302). The centrally evoked food intake
(appetite stimulation) effect is predominantly mediated by NPY Y1
receptors and causes increase in body fat stores and obesity
(Stanley et al., (1989) Physiology and Behavior 46:173-177).
[0274] According to the present invention, a method for treatment
of anorexia comprises administering to a host subject an effective
amount of an inhibitor(s) to stimulate the appetite and increase
body fat stores which thereby substantially relieves the symptoms
of anorexia.
[0275] A method for treatment of hypotension comprises
administering to a host subject an effective amount of an
inhibitor(s) of the present invention to mediate vasoconstriction
and increase blood pressure which thereby substantially relieves
the symptoms of hypotension.
[0276] DPIV has also been implicated in the metabolism and
inactivation of growth hormone-releasing factor (GHRF). GHRF is a
member of the family of homologous peptides that includes glucagon,
secretin, vasoactive intestinal peptide (VIP), peptide histidine
isoleucine (PHI), pituitary adenylate cyclase activating peptide
(PACAP), gastric inhibitory peptide (GIP) and helodermin. Kubiak et
al. (1994) Peptide Res 7:153. GHRF is secreted by the hypothalamus,
and stimulates the release of growth hormone (GH) from the anterior
pituitary. Thus, the subject method can be used to improve clinical
therapy for certain growth hormone deficient children, and in
clinical therapy of adults to improve nutrition and to alter body
composition (muscle vs. fat). The subject method can also be used
in veterinary practice, for example, to develop higher yield milk
production and higher yield, leaner livestock.
[0277] (iv). Assays of Insulinotropic Activity
[0278] In selecting a compound suitable for use in the subject
method, it is noted that the insulinotropic property of a compound
may be determined by providing that compound to animal cells, or
injecting that compound into animals and monitoring the release of
immunoreactive insulin (IRI) into the media or circulatory system
of the animal, respectively. The presence of IRI can be detected
through the use of a radioimmunoassay which can specifically detect
insulin.
[0279] The db/db mouse is a genetically obese and diabetic strain
of mouse. The db/db mouse develops hyperglycemia and
hyperinsulinemia concomitant with its development of obesity and
thus serves as a model of obese type 2 diabetes (NIDDM). The db/db
mice can purchased from, for example, The Jackson Laboratories (Bar
Harbor, Me.). In an exemplary embodiment, for treatment of the mice
with a regimen including an inhibitor(s) or control, sub-orbital
sinus blood samples are taken before and at some time (e.g., 60
minutes) after dosing of each animal. Blood glucose measurements
can be made by any of several conventional techniques, such as
using a glucose meter. The blood glucose levels of the control and
inhibitor(s) dosed animals are compared
[0280] The metabolic fate of exogenous GLP-1 can also be followed
in either nondiabetic and type II diabetic subjects, and the effect
of a candidate inhibitor(s) determined. For instance, a combination
of high-pressure liquid chromatography (HPLC), specific
radioimmunoassays (RIAs), and a enzyme-linked immunosorbent assay
(ELISA), can be used, whereby intact biologically active GLP-1 and
its metabolites can be detected. See, for example, Deacon et al.
(1995) Diabetes 44:1126-1131. To illustrate, after GLP-1
administration, the intact peptide can be measured using an
NH2-terminally directed RIA or ELISA, while the difference in
concentration between these assays and a COOH-terminal-specific RIA
allowed determination of NH2-terminally truncated metabolites.
Without inhibitor, subcutaneous GLP-1 is rapidly degraded in a
time-dependent manner, forming a metabolite which co-elutes on HPLC
with GLP-I(9-36) amide and has the same immunoreactive profile. For
instance, thirty minutes after subcutaneous GLP-1 administration to
diabetic patients (n=8), the metabolite accounted for 88.5+1.9% of
the increase in plasma immunoreactivity determined by the
COOH-terminal RIA, which was higher than the levels measured in
healthy subjects (78.4+3.2%; n=8; P<0.05). See Deacon et al.,
supra. Intravenously infused GLP-I was also extensively
degraded.
[0281] (v). Conjoint Administration
[0282] Another aspect of the invention provides a conjoint therapy
wherein one or more other therapeutic agents are administered with
the protease inhibitor. Such conjoint treatment may be achieved by
way of the simultaneous, sequential or separate dosing of the
individual components of the treatment.
[0283] In one embodiment, an inhibitor(s) is conjointly
administered with insulin or other insulinotropic agents, such as
GLP-1, peptide hormones, such as GLP-2, GIP, or NPY, or a gene
therapy vector which causes the ectopic expression of said agents
and peptide hormones. In certain embodiments, said agents or
peptide hormones may be variants of a naturally occurring or
synthetic peptide hormone, wherein one or more amino acids have
been added, deleted or substituted.
[0284] In another illustrative embodiment, the subject inhibitors
can be conjointly administered with a an M1 receptor antagonist.
Cholinergic agents are potent modulators of insulin release that
act via muscarinic receptors. Moreover, the use of such agents can
have the added benefit of decreasing cholesterol levels, while
increasing HDL levels. Suitable muscarinic receptor antagonists
include substances that directly or indirectly block activation of
muscarinic cholinergic receptors. Preferably, such substances are
selective (or are used in amounts that promote such selectivity)
for the Ml receptor. Nonlimiting examples include quaternary amines
(such as methantheline, ipratropium, and propantheline), tertiary
amines (e.g. dicyclomine, scopolamine) and tricyclic amines (e.g.
telenzepine). Pirenzepine and methyl scopolamine are preferred.
Other suitable muscarinic receptor antagonists include benztropine
(commercially available as COGENTINfrom Merck),
hexahydro-sila-difenidol hydrochloride (HHSID hydrochloride
disclosed in Lambrecht et al. (1989) Trends in Pharmacol. Sci.
10(Suppl):60; (+/-)-3-quinuclidinyl xanthene-9-carboxylate
hemioxalate (QNX-hemioxalate; Birdsall et al., Trends in Pharmacol.
Sci. 4:459, 1983; telenzepine dihydrochloride (Coruzzi et al.
(1989) Arch. Int. Pharmacodyn. Ther. 302:232; and Kawashima et al.
(1990) Gen. Pharmacol. 21:17) and atropine. The dosages of such
muscarinic receptor antagonists will be generally subject to
optimization as outlined above. In the case of lipid metabolism
disorders, dosage optimization may be necessary independently of
whether administration is timed by reference to the lipid
metabolism responsiveness window or not.
[0285] In terms of regulating insulin and lipid metabolism and
reducing the foregoing disorders, the subject inhibitor(s) may also
act synergistically with prolactin inhibitors such as d2 dopamine
agonists (e.g. bromocriptine). Accordingly, the subject method can
include the conjoint administration of such prolactin inhibitors as
prolactin-inhibiting ergo alkaloids and prolactin-inhibiting
dopamine agonists. Examples of suitable compounds include
2-bromo-alpha-ergocriptine, 6-methyl-8
beta-carbobenzyloxyaminoethyl-10-alpha-ergoline,
8-acylaminoergolines, 6-methyl-8-alpha-(N-acyl)amino-9-ergoline,
6-methyl-8-alpha-(N-phenylacetyl)amino-9-ergoline, ergocornine,
9,10-dihydroergocornine, D-2-halo-6-alkyl-8-substituted ergolines,
D-2-bromo-6-methyl-8-cyanomethylergoline, carbidopa, benserazide
and other dopadecarboxylase inhibitors, L-dopa, dopamine and non
toxic salts thereof.
[0286] The inhibitor(s) used according to the invention can also be
used conjointly with agents acting on the ATP-dependent potassium
channel of the .beta.-cells, such as glibenclamide, glipizide,
gliclazide and AG-EE 623 ZW. The inhibitor(s) may also
advantageously be applied in combination with other oral agents
such as metformin and related compounds or glucosidase inhibitors
as, for example, acarbose.
[0287] (vi). Pharmaceutical Compositions
[0288] Inhibitors prepared as described herein can be administered
in various forms, depending on the disorder to be treated and the
age, condition and body weight of the patient, as is well known in
the art. For example, where the compounds are to be administered
orally, they may be formulated as tablets, capsules, granules,
powders or syrups; or for parenteral administration, they may be
formulated as injections (intravenous, intramuscular or
subcutaneous), drop infusion preparations or suppositories. For
application by the ophthalmic mucous membrane route, they may be
formulated as eyedrops or eye ointments. These formulations can be
prepared by conventional means, and, if desired, the active
ingredient may be mixed with any conventional additive, such as an
excipient, a binder, a disintegrating agent, a lubricant, a
corrigent, a solubilizing agent, a suspension aid, an emulsifying
agent or a coating agent. Although the dosage will vary depending
on the symptoms, age and body weight of the patient, the nature and
severity of the disorder to be treated or prevented, the route of
administration and the form of the drug, in general, a daily dosage
of from 0.01 to 2000 mg of the compound is recommended for an adult
human patient, and this may be administered in a single dose or in
divided doses.
[0289] The precise time of administration and/or amount of the
inhibitor that will yield the most effective results in terms of
efficacy of treatment in a given patient will depend upon the
activity, pharmacokinetics, and bioavailability of a particular
compound, physiological condition of the patient (including age,
sex, disease type and stage, general physical condition,
responsiveness to a given dosage and type of medication), route of
administration, etc. However, the above guidelines can be used as
the basis for fine-tuning the treatment, e.g., determining the
optimum time and/or amount of administration, which will require no
more than routine experimentation consisting of monitoring the
subject and adjusting the dosage and/or timing.
[0290] The phrase "pharmaceutically acceptable" is employed herein
to refer to those ligands, materials, compositions, and/or dosage
forms which are, within the scope of sound medical judgment,
suitable for use in contact with the tissues of human beings and
animals without excessive toxicity, irritation, allergic response,
or other problem or complication, commensurate with a reasonable
benefit/risk ratio.
[0291] The phrase "pharmaceutically acceptable carrier" as used
herein means a pharmaceutically acceptable material, composition or
vehicle, such as a liquid or solid filler, diluent, excipient,
solvent or encapsulating material, involved in carrying or
transporting the subject chemical from one organ, or portion of the
body, to another organ, or portion of the body. Each carrier must
be "acceptable" in the sense of being compatible with the other
ingredients of the formulation and not injurious to the patient.
Some examples of materials which can serve as pharmaceutically
acceptable carriers include: (1) sugars, such as lactose, glucose
and sucrose; (2) starches, such as corn starch and potato starch;
(3) cellulose, and its derivatives, such as sodium carboxymethyl
cellulose, ethyl cellulose and cellulose acetate; (4) powdered
tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such
as cocoa butter and suppository waxes; (9) oils, such as peanut
oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil
and soybean oil; (10) glycols, such as propylene glycol; (11)
polyols, such as glycerin, sorbitol, mannitol and polyethylene
glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13)
agar; (14) buffering agents, such as magnesium hydroxide and
aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water;
(17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol;
(20) phosphate buffer solutions; and (21) other non-toxic
compatible substances employed in pharmaceutical formulations.
[0292] The term "pharmaceutically acceptable salts" refers to the
relatively non-toxic, inorganic and organic acid addition salts of
the inhibitor(s). These salts can be prepared in situ during the
final isolation and purification of the inhibitor(s), or by
separately reacting a purified inhibitor(s) in its free base form
with a suitable organic or inorganic acid, and isolating the salt
thus formed. Representative salts include the hydrobromide,
hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate,
valerate, oleate, palmitate, stearate, laurate, benzoate, lactate,
phosphate, tosylate, citrate, maleate, fumarate, succinate,
tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and
laurylsulphonate salts and the like. (See, for example, Berge et
al. (1977) "Pharmaceutical Salts", J. Pharm. Sci. 66:1-19)
[0293] In other cases, the inhibitors useful in the methods of the
present invention may contain one or more acidic functional groups
and, thus, are capable of forming pharmaceutically acceptable salts
with pharmaceutically acceptable bases. The term "pharmaceutically
acceptable salts" in these instances refers to the relatively
non-toxic, inorganic and organic base addition salts of an
inhibitor(s). These salts can likewise be prepared in situ during
the final isolation and purification of the inhibitor(s), or by
separately reacting the purified inhibitor(s) in its free acid form
with a suitable base, such as the hydroxide, carbonate or
bicarbonate of a pharmaceutically acceptable metal cation, with
ammonia, or with a pharmaceutically acceptable organic primary,
secondary or tertiary amine. Representative alkali or alkaline
earth salts include the lithium, sodium, potassium, calcium,
magnesium, and aluminum salts and the like. Representative organic
amines useful for the formation of base addition salts include
ethylamine, diethylamine, ethylenediamine, ethanolamine,
diethanolamine, piperazine and the like (see, for example, Berge et
al., supra).
[0294] Wetting agents, emulsifiers and lubricants, such as sodium
lauryl sulfate and magnesium stearate, as well as coloring agents,
release agents, coating agents, sweetening, flavoring and perfuming
agents, preservatives and antioxidants can also be present in the
compositions.
[0295] Examples of pharmaceutically acceptable antioxidants
include: (1) water soluble antioxidants, such as ascorbic acid,
cysteine hydrochloride, sodium bisulfate, sodium metabisulfite,
sodium sulfite and the like; (2) oil-soluble antioxidants, such as
ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated
hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol,
and the like; and (3) metal chelating agents, such as citric acid,
ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid,
phosphoric acid, and the like.
[0296] Formulations useful in the methods of the present invention
include those suitable for oral, nasal, topical (including buccal
and sublingual), rectal, vaginal, aerosol and/or parenteral
administration. The formulations may conveniently be presented in
unit dosage form and may be prepared by any methods well known in
the art of pharmacy. The amount of active ingredient which can be
combined with a carrier material to produce a single dosage form
will vary depending upon the host being treated, the particular
mode of administration. The amount of active ingredient which can
be combined with a carrier material to produce a single dosage form
will generally be that amount of the compound which produces a
therapeutic effect. Generally, out of one hundred percent, this
amount will range from about 1 percent to about ninety-nine percent
of active ingredient, preferably from about 5 percent to about 70
percent, most preferably from about 10 percent to about 30
percent.
[0297] Methods of preparing these formulations or compositions
include the step of bringing into association an inhibitor(s) with
the carrier and, optionally, one or more accessory ingredients. In
general, the formulations are prepared by uniformly and intimately
bringing into association a ligand with liquid carriers, or finely
divided solid carriers, or both, and then, if necessary, shaping
the product.
[0298] Formulations suitable for oral administration may be in the
form of capsules, cachets, pills, tablets, lozenges (using a
flavored basis, usually sucrose and acacia or tragacanth), powders,
granules, or as a solution or a suspension in an aqueous or
non-aqueous liquid, or as an oil-in-water or water-in-oil liquid
emulsion, or as an elixir or syrup, or as pastilles (using an inert
base, such as gelatin and glycerin, or sucrose and acacia) and/or
as mouthwashes and the like, each containing a predetermined amount
of an inhibitor(s) as an active ingredient. A compound may also be
administered as a bolus, electuary or paste.
[0299] In solid dosage forms for oral administration (capsules,
tablets, pills, dragees, powders, granules and the like), the
active ingredient is mixed with one or more pharmaceutically
acceptable carriers, such as sodium citrate or dicalcium phosphate,
and/or any of the following: (1) fillers or extenders, such as
starches, lactose, sucrose, glucose, mannitol, and/or silicic acid;
(2) binders, such as, for example, carboxymethylcellulose,
alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia;
(3) humectants, such as glycerol; (4) disintegrating agents, such
as agar-agar, calcium carbonate, potato or tapioca starch, alginic
acid, certain silicates, and sodium carbonate; (5) solution
retarding agents, such as paraffin; (6) absorption accelerators,
such as quaternary ammonium compounds; (7) wetting agents, such as,
for example, acetyl alcohol and glycerol monostearate; (8)
absorbents, such as kaolin and bentonite clay; (9) lubricants, such
a talc, calcium stearate, magnesium stearate, solid polyethylene
glycols, sodium lauryl sulfate, and mixtures thereof; and (10)
coloring agents. In the case of capsules, tablets and pills, the
pharmaceutical compositions may also comprise buffering agents.
Solid compositions of a similar type may also be employed as
fillers in soft and hard-filled gelatin capsules using such
excipients as lactose or milk sugars, as well as high molecular
weight polyethylene glycols and the like.
[0300] A tablet may be made by compression or molding, optionally
with one or more accessory ingredients. Compressed tablets may be
prepared using binder (for example, gelatin or hydroxypropylmethyl
cellulose), lubricant, inert diluent, preservative, disintegrant
(for example, sodium starch glycolate or cross-linked sodium
carboxymethyl cellulose), surface-active or dispersing agent.
Molded tablets may be made by molding in a suitable machine a
mixture of the powdered peptide or peptidomimetic moistened with an
inert liquid diluent.
[0301] Tablets, and other solid dosage forms, such as dragees,
capsules, pills and granules, may optionally be scored or prepared
with coatings and shells, such as enteric coatings and other
coatings well known in the pharmaceutical-formulating art. They may
also be formulated so as to provide slow or controlled release of
the active ingredient therein using, for example,
hydroxypropylmethyl cellulose in varying proportions to provide the
desired release profile, other polymer matrices, liposomes and/or
microspheres. They may be sterilized by, for example, filtration
through a bacteria-retaining filter, or by incorporating
sterilizing agents in the form of sterile solid compositions which
can be dissolved in sterile water, or some other sterile injectable
medium immediately before use. These compositions may also
optionally contain opacifying agents and may be of a composition
that they release the active ingredient(s) only, or preferentially,
in a certain portion of the gastrointestinal tract, optionally, in
a delayed manner. Examples of embedding compositions which can be
used include polymeric substances and waxes. The active ingredient
can also be in micro-encapsulated form, if appropriate, with one or
more of the above-described excipients.
[0302] Liquid dosage forms for oral administration include
pharmaceutically acceptable emulsions, microemulsions, solutions,
suspensions, syrups and elixirs. In addition to the active
ingredient, the liquid dosage forms may contain inert diluents
commonly used in the art, such as, for example, water or other
solvents, solubilizing agents and emulsifiers, such as ethyl
alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl
alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol,
oils (in particular, cottonseed, groundnut, corn, germ, olive,
castor and sesame oils), glycerol, tetrahydrofuryl alcohol,
polyethylene glycols and fatty acid esters of sorbitan, and
mixtures thereof.
[0303] Besides inert diluents, the oral compositions can also
include adjuvants such as wetting agents, emulsifying and
suspending agents, sweetening, flavoring, coloring, perfuming and
preservative agents.
[0304] Suspensions, in addition to the active inhibitor(s) may
contain suspending agents as, for example, ethoxylated isostearyl
alcohols, polyoxyethylene sorbitol and sorbitan esters,
microcrystalline cellulose, aluminum metahydroxide, bentonite,
agar-agar and tragacanth, and mixtures thereof.
[0305] Formulations for rectal or vaginal administration may be
presented as a suppository, which may be prepared by mixing one or
more inhibitor(s) with one or more suitable nonirritating
excipients or carriers comprising, for example, cocoa butter,
polyethylene glycol, a suppository wax or a salicylate, and which
is solid at room temperature, but liquid at body temperature and,
therefore, will melt in the rectum or vaginal cavity and release
the active agent.
[0306] Formulations which are suitable for vaginal administration
also include pessaries, tampons, creams, gels, pastes, foams or
spray formulations containing such carriers as are known in the art
to be appropriate.
[0307] Dosage forms for the topical or transdermal administration
of an inhibitor(s) include powders, sprays, ointments, pastes,
creams, lotions, gels, solutions, patches and inhalants. The active
component may be mixed under sterile conditions with a
pharmaceutically acceptable carrier, and with any preservatives,
buffers, or propellants which may be required.
[0308] The ointments, pastes, creams and gels may contain, in
addition to inhibitor(s), excipients, such as animal and vegetable
fats, oils, waxes, paraffins, starch, tragacanth, cellulose
derivatives, polyethylene glycols, silicones, bentonites, silicic
acid, talc and zinc oxide, or mixtures thereof.
[0309] Powders and sprays can contain, in addition to an
inhibitor(s), excipients such as lactose, talc, silicic acid,
aluminum hydroxide, calcium silicates and polyamide powder, or
mixtures of these substances. Sprays can additionally contain
customary propellants, such as chlorofluorohydrocarbons and
volatile unsubstituted hydrocarbons, such as butane and
propane.
[0310] The inhibitor(s) can be alternatively administered by
aerosol. This is accomplished by preparing an aqueous aerosol,
liposomal preparation or solid particles containing the compound. A
nonaqueous (e.g., fluorocarbon propellant) suspension could be
used. Sonic nebulizers are preferred because they minimize exposing
the agent to shear, which can result in degradation of the
compound.
[0311] Ordinarily, an aqueous aerosol is made by formulating an
aqueous solution or suspension of the agent together with
conventional pharmaceutically acceptable carriers and stabilizers.
The carriers and stabilizers vary with the requirements of the
particular compound, but typically include nonionic surfactants
(Tweens, Pluronics, or polyethylene glycol), innocuous proteins
like serum albumin, sorbitan esters, oleic acid, lecithin, amino
acids such as glycine, buffers, salts, sugars or sugar alcohols.
Aerosols generally are prepared from isotonic solutions.
[0312] Transdermal patches have the added advantage of providing
controlled delivery of an inhibitor(s) to the body. Such dosage
forms can be made by dissolving or dispersing the agent in the
proper medium. Absorption enhancers can also be used to increase
the flux of the inhibitor(s) across the skin. The rate of such flux
can be controlled by either providing a rate controlling membrane
or dispersing the peptidomimetic in a polymer matrix or gel.
[0313] Ophthalmic formulations, eye ointments, powders, solutions
and the like, are also contemplated as being within the scope of
this invention.
[0314] Pharmaceutical compositions of this invention suitable for
parenteral administration comprise one or more inhibitors(s) in
combination with one or more pharmaceutically acceptable sterile
isotonic aqueous or nonaqueous solutions, dispersions, suspensions
or emulsions, or sterile powders which may be reconstituted into
sterile injectable solutions or dispersions just prior to use,
which may contain antioxidants, buffers, bacteriostats, solutes
which render the formulation isotonic with the blood of the
intended recipient or suspending or thickening agents.
[0315] Examples of suitable aqueous and nonaqueous carriers which
may be employed in the pharmaceutical compositions of the invention
include water, ethanol, polyols (such as glycerol, propylene
glycol, polyethylene glycol, and the like), and suitable mixtures
thereof, vegetable oils, such as olive oil, and injectable organic
esters, such as ethyl oleate. Proper fluidity can be maintained,
for example, by the use of coating materials, such as lecithin, by
the maintenance of the required particle size in the case of
dispersions, and by the use of surfactants.
[0316] These compositions may also contain adjuvants such as
preservatives, wetting agents, emulsifying agents and dispersing
agents. Prevention of the action of microorganisms may be ensured
by the inclusion of various antibacterial and antifungal agents,
for example, paraben, chlorobutanol, phenol sorbic acid, and the
like. It may also be desirable to include isotonic agents, such as
sugars, sodium chloride, and the like into the compositions. In
addition, prolonged absorption of the injectable pharmaceutical
form may be brought about by the inclusion of agents which delay
absorption such as aluminum monostearate and gelatin.
[0317] In some cases, in order to prolong the effect of a drug, it
is desirable to slow the absorption of the drug from subcutaneous
or intramuscular injection. This may be accomplished by the use of
a liquid suspension of crystalline or amorphous material having
poor water solubility. The rate of absorption of the drug then
depends upon its rate of dissolution which, in turn, may depend
upon crystal size and crystalline form. Alternatively, delayed
absorption of a parenterally administered drug form is accomplished
by dissolving or suspending the drug in an oil vehicle.
[0318] Injectable depot forms are made by forming microencapsule
matrices of inhibitor(s) in biodegradable polymers such as
polylactide-polyglycolide. Depending on the ratio of drug to
polymer, and the nature of the particular polymer employed, the
rate of drug release can be controlled. Examples of other
biodegradable polymers include poly(orthoesters) and
poly(anhydrides). Depot injectable formulations are also prepared
by entrapping the drug in liposomes or microemulsions which are
compatible with body tissue.
[0319] When the inhibitors(s) of the present invention are
administered as pharmaceuticals, to humans and animals, they can be
given per se or as a pharmaceutical composition containing, for
example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active
ingredient in combination with a pharmaceutically acceptable
carrier.
[0320] The preparations of agents may be given orally,
parenterally, topically, or rectally. They are of course given by
forms suitable for each administration route. For example, they are
administered in tablets or capsule form, by injection, inhalation,
eye lotion, ointment, suppository, infusion; topically by lotion or
ointment; and rectally by suppositories. Oral administration is
preferred.
[0321] The phrases "parenteral administration" and "administered
parenterally" as used herein means modes of administration other
than enteral and topical administration, usually by injection, and
includes, without limitation, intravenous, intramuscular,
intraarterial, intrathecal, intracapsular, intraorbital,
intracardiac, intradermal, intraperitoneal, transtracheal,
subcutaneous, subcuticular, intraarticular, subcapsular,
subarachnoid, intraspinal and intrasternal injection and
infusion.
[0322] The phrases "systemic administration," "administered
systemically," "peripheral administration" and "administered
peripherally" as used herein mean the administration of a ligand,
drug or other material other than directly into the central nervous
system, such that it enters the patient's system and, thus, is
subject to metabolism and other like processes, for example,
subcutaneous administration.
[0323] These inhibitors(s) may be administered to humans and other
animals for therapy by any suitable route of administration,
including orally, nasally, as by, for example, a spray, rectally,
intravaginally, parenterally, intracisternally and topically, as by
powders, ointments or drops, including buccally and
sublingually.
[0324] Regardless of the route of administration selected, the
inhibitor(s), which may be used in a suitable hydrated form, and/or
the pharmaceutical compositions of the present invention, are
formulated into pharmaceutically acceptable dosage forms by
conventional methods known to those of skill in the art.
[0325] Actual dosage levels of the active ingredients in the
pharmaceutical compositions of this invention may be varied so as
to obtain an amount of the active ingredient which is effective to
achieve the desired therapeutic response for a particular patient,
composition, and mode of administration, without being toxic to the
patient.
[0326] IV. Exemplification
[0327] The invention now being generally described, it will be more
readily understood by reference to the following examples which are
included merely for purposes of illustration of certain aspects and
embodiments of the present invention, and are not intended to limit
the invention.
ABBREVIATIONS
[0328] EDC: N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide
hydrochloride;
[0329] HOBT: 1-Hydroxybenzotriazole;
[0330] Chg: Cyclohexylglycine.
Example 1
Synthesis of Cyclohexylglycine boroAla
[0331] Referring to FIG. 1, a solution of 515 mg (2.00 mmol) of
Boc-L-2-(cyclohexyl)glycine 1 (Chem-Impex International), 587 mg
(2.26 mmol) of HCl.boroAla pinane 2, 332 mg (2.46 mmol) of HOBT,
and 671 .mu.L (4.84 mmol) of triethylamine in 6 mL of anhydrous DMF
was treated with 498 mg (2.60 mmol) of EDC, and the resulting
solution stirred at room temperature under argon for 18 h. The
reaction mixture was diluted with a 200 mL of 10% aqueous citric
acid and the resulting mixture extracted with 2.times.100 mL of
ethyl acetate. The combined extracts were washed with brine, dried
(MgSO.sub.4), filtered, and concentrated to give a clear oil. The
crude oil was chromatographed over silica gel with ethyl
acetate/hexane to give the product ester as a clear oil. The oil
was then dissolved in hydrogen chloride in diethyl ether (1.0 M
solution, 25 mL) and stirred for 48 hours at room temperature. The
mixture was evaporated to dryness in vacuo and redissolved in 25 mL
phenylboronic acid solution (244 mg, 2 mmol) at pH 2 (0.01 N HCl)
and ether (25 mL). After stirring for 30 min, the ether layer was
removed and replaced with fresh ether (25 mL). This step was
repeated for four times. The aqueous phase was then lyophilized and
purified by HPLC to afford 170 mg (37%) of the target compound
3.
Example 2
Glucose Tolerance Test
[0332] Experiments show that cyclohexyl-gly boro ala is orally
active and clearly lowers blood sugar based upon results from an
oral glucose challenge in zucker obese rats. See FIG. 2. In these
"acute" experiments zucker obese and zucker lean rats were orally
administered either 0.035 mg/kg (low dose) or 0.35 mg/kg (high
dose) of cyclohexyl-gly boro ala and then subjected to an oral
glucose tolerance test within an hour. Each set of experiments was
also performed using saline as a control.
Example 3
Inhibitor Inactivation at pH 8
[0333] Experiments show that Cyclohexylglycine-bAla does not show
significant pH-time dependant inhibition as compared with His-bAla,
Ala-bAla, and Phg-bAla. In this experiment stock solutions of
inhibitors (His-bAla, Ala-bAla, Phg-bAla and
Cyclohexylglycine-bAla) were prepared at pH 1-2. These stock
solutions were pre-incubated at pH 8 as follows: first, 1:10
dilutions into a buffer (0.1 M HEPES pH 8, 0.14 M NaCl) were
performed; secondly, the pH was measured after dilution and varied
for different inhibitors between 7.5 and 8; and thirdly,
incubations at this pH were performed for 0, 60, 120, 180 minutes.
Following incubation, 1:10 serial dilutions of inhibitors in buffer
and 1:10 dilution of inhibitors into Enzyme (DPPIV) in buffer were
made. The inhibitors were pre-incubated with enzyme for 10 minutes
to account for slow binding and substrate
(H-Ala-Pro-paranitoranalide) was added at a concentration of
approx.=KM (17 .mu.M). Absorbances at 410 nm were recorded for all
inhibitors after 30 minutes. See FIGS. 3-6.
Example 4
DPPIV Assays on Serum Samples from Rats
[0334] Experiments show that DPPIV enzyme activity was
significantly decreased in rats treated with
Cyclohexylglycine-boroAla. See FIG. 7. Four rats were used in this
experiment: two females (#3 and #9) and two males (#10 and #11).
Blood and plasma samples were collected from rats 1 hour after
being treated with Cyclohexylglycine-boroAla. The collected serum
samples were evaluated for DPPIV activity of
Cyclohexylglycine-boroAla as follows: [0335] 2 mg of
Ala-Pro-paranitroanalide (substrate) was dissolved in 20 ml 0.1 M
HEPES pH 8, 0.14 M NaCl (buffer). [0336] Serum samples were diluted
into substrate solution in the wells of a microtiter plate. For
each sample, 10 uL of serum was diluted into 150 .mu.L of
substrate. [0337] A reading of the A410 in each well was recorded
immediately after the dilution of serum into substrate, and again
after approximately 1 hour. The time of data acquisition for each
reading is recorded in the data file by the microplate reader
software.
[0338] The rate of absorbance change was obtained by subtracting
the first reading from the second and dividing by the reaction time
to give DeltaA410/hr. The DPPIV activity was plotted in units of
DeltaA410 hr.sup.-1 .mu.L.sup.-1.
Example 5
Prevention of Cyclization by Using Bulky Substituents
[0339] In this example, Xaa-boro-Ala analogs containing bulky R
substituent will be constructed to prevent cyclization and increase
biological activity. See FIG. 8. The inventors have previously
shown that synthetic diastereomeric monomeric compounds, e.g.,
L-Ala-D, L-boroPro and L-Pro-D, L-boroPro, were potent inhibitors
of the catalytic activity of soluble DPIV. They also encountered a
problem because these monomeric inhibitors lost some of their
inhibitory activity rapidly in aqueous solution at pH value around
neutral due to a cyclization reaction. The open, active, inhibitory
chain species is favored at low pH while the cyclized structure is
favored at high pH. Also, the reaction is fully reversible: the
open chain becomes predominate at low pH. The open chain to cyclic
species reaction involves a trans to cis isomerization of the
proline and the formation of a new N--B bond. The half life for the
reformation of the open chain species from the cyclic structure is
surprisingly slow. It has been demonstrated that the ratio of
[cyclic]: [open] forms, at neutral pH, is 156:1 for Pro-boroPro and
1130:1 for Val-boroPro (W. G. Gutheil and W. W. Bachovchin,
Separation of L-Pro-DL-boroPro into Its Component Diastereomers and
Kinetic Analysis of Their Inhibition of Dipeptidyl Peptidase IV. A
New Method for the Analysis of Slow, Tight-Binding Inhibition,
Biochemistry 32, 8723-8731 (1993)). This means that less than 1%
Pro-boroPro and less than 0.1% of Val-boroPro exists as the open
chain, inhibitory species, at equilibrium at pH 7.0.
[0340] One feature of the present invention relates to the
equilibrium constant for cyclization. It has been found that the
ratio of [cyclic]:[open] forms for Cyclohexylglycine-boro-Ala, at
neutral pH, is approximately 2:1, which is significantly lower than
the corresponding ratio for Xaa-boro-Pro, as previously disclosed.
In addition, the cis-trans isomerization rate, and therefore the
rates of cyclization and uncyclization, are also much faster for
compounds of the present invention. This feature is attributed by
the inventors to a bulky substituent effect, e.g. where R in FIG. 8
represents a cyclohexyl.
[0341] The inventors predict that biological bioavailability
(biological function) for the compounds taught in this invention
could be significantly increased (approximately 100-1000 times) by
preventing peptide conformational changes, e.g., intramolecular
cyclization, by constructing compounds bearing a variety of bulky R
groups (see FIG. 8). Such compounds include but are not limited to
compounds containing unnaturally occurring amino acids at P2.
[0342] IV. Equivalents
[0343] Those skilled in the art will recognize, or be able to
ascertain using no more than routine experimentation, many
equivalents to the specific embodiments of the invention described
herein. Such equivalents are intended to be encompassed by the
following claims.
[0344] All of the above-cited references and publications are
hereby incorporated by reference.
* * * * *